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Feline immunodeficiency virus is an important lentiviral infection in cats. Infection is life-long 
and results in immune compromise, increased susceptibility to opportunistic infections and early 
mortality. Infection is commonly referred to in three stages: acute, (asymptomatic) and end stage 
(symptomatic); although not all cats will progress to end stage disease. Acute infection lasts 
several months during which cats may have mild, transient anorexia, lethargy, fever, 
lymphadenomegaly and diarrhea. There is loss of mucosal and peripheral CD4 T cells, expansion 
of a subset of CD8 T cells, CD8βlow, and establishment of viremia during this period. 
Asymptomatic infection lasts a variable period of years during which progressive decreases in 
CD4 T cells and inversion of the CD4:CD8 ratio occurs. End stage infection does not occur in all 
infected cats. It is characterized by a rapid decline in health including generalized muscle 
wasting, treatment-refractory opportunistic infection and / or neoplasia leading to death within 
months. A marked decrease in CD4 T cell counts and CD4:CD8 ratio and several fold increase in 
viremia occurs during end stage disease but reported literature is sparse. Longitudinal studies of 
specific pathogen free cats experimentally infected with FIV infection have focused primarily on 
acute and early asymptomatic stages of infection. Little has been reported on the transition from 
late chronic to end stage disease. Longitudinal studies of cats naturally infected with FIV are 
needed to better characterize the course of infection. 
In this study, a cohort of cats naturally infected with FIV (n = 87) and uninfected cats (n = 87) 
were monitored over a period of 3 to 5 years, depending on when they were enrolled. FIV-
infected cats were examined twice yearly and uninfected were examined once yearly. At each 
examination blood samples were collected for routine hematological and biochemical screening 
xi 
 
and lymphocyte immunophenotyping. It was hypothesized that  FIV-infected cats, compared to 
FIV-uninfected cats, will have: 1) an increased rate of illness and mortality; 2) differences in 
temporal patterns for routine hematological and biochemical tests, and lymphocyte 
immunophenotype; and 3) changes in lymphocyte immunophenotype and clinical pathology 
markers associated with illness and mortality rates. The same hypotheses were also tested 
between FIV-infected cats in sanctuary housing and FIV-infected cats living in private homes of 
<7 cats. 
Results showed that mortality rate was increased by 11.7 fold in FIV-infected cats in sanctuary 
housing and 4.1 fold in FIV-infected cats in private homes compared to FIV-uninfected cats. 
Illness rates were increased 15.1 fold higher in sanctuary housed cats and 3.0 fold higher in 
privately homed cats compared to FIV-uninfected cats. FIV-infected cats in sanctuary housing 
had a 5.1 fold increased mortality rate associated with FIV infection compared to FIV-infected 
cats living in private homes. 
Differences in temporal patterns were statistically significantly different for absolute CD4 T cell 
counts, total CD8 T cell counts, lymphocytes numbers, albumin, blood urea nitrogen (BUN), and 
cholesterol levels for FIV-infected cats compared to uninfected cats. Although T cell and 
lymphocyte counts decreased in both groups, the decreases were greater for FIV-infected cats. 
Albumin and BUN values decreased and globulin values increased in FIV-infected cats compared 
to uninfected cats but the changes were small. Differences in CD8βlow cells counts, CD4:CD8 
ratio, globulin and total protein levels were seen but remained stable between the groups over 
time. FIV-infected cats in sanctuary housing showed statistically significantly different temporal 
patterns for absolute white blood cell counts (WBC), hematocrit, total protein (TP), BUN, 
creatinine and alanine aminotransferase (ALT) but the changes were small. WBC and TP values 
increased in FIV-infected cats in sanctuary housing compared to cats in private homes. 
Decreasing temporal patterns in BUN, creatinine, ALT and hematocrit were found in FIV-
infected cats in sanctuary housing compared to cats in private homes but changes were small and 
median values remained within the reference intervals. Higher absolute neutrophil counts and 
globulin levels and lower values for albumin and cholesterol levels were seen in FIV-infected cats 
in sanctuary housing compared to cats in private homes but differences remained stable between 
the two groups. 
xii 
 
In FIV-infected cats, a greater decrease in CD4 T cell and albumin percentages and a greater 
increase in CD4:CD8 ratios and neutrophil counts were associated with an increase in illness rate. 
An increase in mortality rate was associated with a greater increase in total protein and greater 
decreased in albumin and hematocrit percentages. However, associations were weak and use of 
any of these parameters as a stand-alone monitoring tool cannot be recommended.  There were no 
associations between any parameter and illness or mortality in FIV-uninfected cats. 
Results of this study showed FIV-infected cats had increased illness and mortality rates compared 
to FIV-uninfected cats. Furthermore, FIV-infected cats living in sanctuary housing had higher 
illness and mortality rates compared to FIV-infected cats living in private housing. This raises the 
question of what role environmental conditions may play in disease progression in FIV infection. 
This has not been previously reported in the literature and further investigation into the potential 
environmental impact on disease progression is warranted. 
The most notable differences in temporal patterns for health parameters were associated with 
inflammation and immune cells. Illness and mortality rates were associated with greater changes 
in inflammatory parameters and lymphocyte immunophenotype in FIV-infected cats, although, 
associations were weak. While considered exploratory in this study population, these findings 
further support the roles of chronic inflammation and immune activation in disease progression 
following FIV infection that have been reported in the literature. Given the limited availability of 
monitoring techniques for FIV-infected cats, further investigation into the use of these health 
markers of inflammation and lymphocyte immunophenotype as a panel to monitor disease 
progression is warranted. However, continued research into new, reliable and easily performed 








Feline immunodeficiency virus (FIV) is an important worldwide lentiviral disease in cats similar 
to human immunodeficiency (HIV) and simian immunodeficiency virus (SIV). Worldwide 
disease prevalence has been reported between 2 and 34% depending on location, living 
environment and health of the cat1,2. FIV is a complicated lifelong disease that results in 
immunocompromise and a chronic inflammatory state within the host. Infection is most 
commonly spread through deep, penetrating bite wounds and male, intact, outdoor cats are 
considered at highest risk due to territorial fighting behavior3,4. 
Following infection there are 3 stages of infection: acute, chronic (asymptomatic) and end stage 
(symptomatic). In the acute stage of infection, cats may experience transient clinical signs of 
illness including fever, lethargy, anorexia and diarrhea beginning approximately 6-8 weeks post-
infection5. Mucosal and peripheral blood CD4 T cell populations are greatly reduced, CD8βlow T 
cell populations are expanded and viremia is established5-8. The expansion of CD8βlow cells 
appears to be unique to FIV infection and studies have shown that as this population of cells is 
expanded viremia is decreased9. However, infected cats are unable to clear the virus resulting in 
life-long infection and persistent low level viremia10,11. Once viremia is brought under control, 
CD4 T cell counts recover but typically not to pre-infection levels and cats transitions into a 
chronic asymptomatic phase of infection which lasts a variable period of years. During this time, 
cats have no detectable abnormalities on physical examination. There is, however, a gradual 
decrease in CD4 T cell counts, expansion of CD8βlow cells, progressive inversion of the 
CD4:CD8 ratio, and an undulating viral burden which at times is below the limit of detection10,12. 
Progressive immune alteration eventually results in immunocompromise and may increase 
susceptibility to certain infections and neoplasias. It is not known what proportion of cats will 
progress to end stage infection. However, it is known that once in the end stage of infection, 
decline in health is rapid, typically over several months, and death is imminent. Of cats that do 
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progress to end stage infection, treatment refractory opportunistic infections, generalized muscle 
wasting, chronic gastrointestinal disease and neoplasia are common13,14. It is thought that cats in 
end stage infection have a resurgence of viremia, extreme loss of CD4 T cells, and marked 
anemia and leukopenia, however, this has not been extensively studied15-17. 
Several underlying mechanisms of immunocompromise and chronic inflammation are similar 
between FIV, HIV and SIV; although mechanisms in HIV have been more intensively studied 
and reported. For example, in FIV-infected cats, cytokine dysregulation, increased T cell anergy 
and apoptosis, and increased regulatory T cell (Treg) activity have been associated with FIV 
disease progression18. Altered cytokine production resulting in increased circulating pro-
inflammatory cytokines such as interleukin-6 (IL-6), IL-1, IL-10, and tumor necrosis factor alpha 
(TNF-α) and decreased IL-12;  favors humoral (antibody) immunity and limits cell-mediated 
immunity, leaving infected cats unable to mount an appropriate immune response to intracellular 
pathogens19-22. Treg cell activation limits the amount of IL-2 produced; a key cytokine produced 
by T cells to propagate an adaptive immune response to pathogens23. Up-regulation and 
overexpression of several surface proteins on activated T cells, namely CTLA-4 and B7.1, act as 
co-stimulatory signals between T cells and induce a state of anergy (immune inactivity)24,25. 
These factors may create a paradoxical situation, in which, immune activation stimulates 
dampening of the adaptive immune response, rather than proliferation of a protective response. 
Similar activity has been reported in HIV and SIV. 
The body of knowledge regarding the immune response following FIV infection has been gleaned 
from experimental studies. Experimental longitudinal studies tend to focus primarily on acute and 
early chronic infection5,6,21, with limited studies on the transition from chronic to end stage 
infection15,16. In contrast, studies of natural infection tend to be cross-sectional studies that 
reported seroprevalence and / or mean differences in health markers between FIV-infected and 
uninfected cats at one point in time 3,26,27. Several factors complicate long term studies of FIV, 
whether experimentally or naturally acquired, including the long duration of infection, 
uncertainty of which cats will progress to end stage infection, lack of known factors that underlie 
disease progression, and the expense associated with monitoring cats over a prolonged period of 
time. Some investigators have expressed concern that experimentally induced infection may not 
accurately mimic naturally acquired infection10. Infecting dose is unknown, as is the impact of 
different inoculating routes, and pathogen exposure disparity between specific pathogen free 
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housing of experimental settings and the variety of housing conditions for privately owned and 
shelter housed cats.  
To date there are no readily available monitoring methods for characterizing immune system 
function changes or for predicting which FIV-infected cats will progress to end stage disease and 
when. Current monitoring guidelines for FIV-infected cats include twice yearly physical 
examinations and once yearly routine hematological and biochemical screenings28,29. While 
important, these screenings only report hematological or biochemical abnormalities and do not 
evaluate immune activation or inflammatory mediators. 
The study reported here monitored a cohort of naturally FIV-infected cats living in either 
sanctuary housing or private homes and FIV-uninfected cats over a period of up to 5 years. 
During the study period, FIV-infected cars were examined twice yearly and FIV-uninfected cats 
were examined once yearly. At each examination blood and urine was collected for routine 
hematological and biochemical screening as well as lymphocyte immunophenotyping. Physical 
examination and laboratory data were assessed and used to calculate illness and mortality rates, 
assess for differences in temporal patterns for laboratory parameters, and for association of 
inflammatory, immunophenotype and hepatic markers with illness and mortality in FIV-infected 
and FIV-uninfected cats. 
The study was designed to address the following hypotheses: FIV-infected cats, compared to 
FIV-uninfected cats will have: 1) higher illness and mortality rates; 2) differences in temporal 
patterns of change CD4 and total CD8 lymphocyte counts and ratios, and hematological and 
biochemical parameters; and 3) changes in markers of inflammation, lymphocyte 
immunophenotype associated with illness and mortality rates over the 1 year interval prior to 
progression to illness or death. These hypotheses were also examined for FIV-infected cats in 
sanctuary housing compared to FIV-infected cats in private homes of <7 cats. 
The information gained from this study will be important for privately owned cats, and also for 
FIV-infected shelter housed cats. These cats represent an emerging population as animal 
sheltering systems move toward a model where FIV-infected cats are placed for adoption rather 
than euthanized. Cats housed in shelters live within a dynamic housing environment and face 
higher exposure to pathogens than do cats living in private homes with smaller numbers of cats. 
For FIV-infected cats, the shelter environment, with ongoing exposure to new cats and pathogens, 
places further stress on the FIV-altered immune system. Without other readily available 
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diagnostics to assess disease progression in FIV-infected cats, identification of easily monitored 
markers associated with illness and mortality is important for maintaining the health of these cats. 
In a broader scope, these findings may help guide future husbandry and management strategies to 
maximize health in FIV-infected cats, particularly shelter housed cats where improved knowledge 
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Feline immunodeficiency virus (FIV) is an important infectious disease affecting cats worldwide. 
The seroprevalence of antibodies to FIV infection in various worldwide cat populations varies 
and has been reported to be between 2% and 34%1-14. Seroprevalence is higher in adult, male cats 
with outdoor access and has been reported to be higher in cats presented to veterinarians with 
clinical signs of illness than in healthy cats6,13-15. The virus is most commonly spread through 
deep, penetrating bite wounds and the higher infection prevalence in intact, outdoor, male cats is 
thought to be due to territorial fighting behavior. 
Similar to human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), the 
FIV course of infection can generally be divided into an acute phase of several months, a variable 
period of chronic asymptomatic infection lasting a variable number of years and finally 
progression to severe immunodeficiency and end stage disease16-19. The viruses cause chronic 
immune activation and impaired response to infection, with immune compromise and eventually 
poor health. There is progressive loss of circulating CD4 T cells leading to persistent inversion of 
the CD4:CD8 ratio20-24, and loss of structural immune integrity including disruption of the 
intestinal barrier and depletion of mucosal immune cells25-31. As a result of progressive immune 
compromise during the chronic phase of infection, patients are at risk for developing certain 
diseases and opportunistic infections such as neoplasia, periodontal disease, chronic 
gingivostomatitis, and upper respiratory infections18,19,32. In the early symptomatic stage of 
infection oral, respiratory, dermal and intestinal infections are common but typically respond to 
medical management and care. However, progression to end stage immunodeficiency often leads 
to treatment-refractory opportunistic infections, wasting, anemia, leukopenia, neoplasia, and 
death17,24,33. In humans, CD4 T cell counts and viral load are routinely monitored to assess the 
need for medical intervention with anti-retroviral therapies (ART) and to evaluate response to 
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ART34,35. However, in some HIV-infected individuals, there is progression to end stage disease 
despite vigilant monitoring and positive response to ART therapies36,37. It has been reported that 
progression of disease in such individuals may be related to chronic immune activation38, and that 
microbial translocation from the intestinal lumen to systemic circulation is an underlying cause of 
chronic immune activation26,39. Patients evaluated had bacterial 16S rRNA, lipopolysaccharide 
(LPS), and increased lipopolysaccharide binding protein (LBP) in circulation as well as increased 
serum concentrations of the inflammatory cytokines interleukin-1β (IL-1β), IL-6, soluble CD14 
(sCD14), and tumor necrosis factor alpha (TNF-α), supporting the hypothesis that microbial 
translocation is associated with chronic immune activation and HOV disease progression26,40. As 
a result, these cytokine biomarkers are being considered for routine monitoring of HIV-infected 
persons to assess and predict disease progression. 
Monitoring of CD4 T cell counts and viral loads is not readily available for use in FIV-infected 
cats and ART therapies are not widely recommended due to serious adverse effects41-45. 
Recommendations for monitoring FIV-infected cats currently include twice yearly physical 
examinations and yearly routine hematological and serum biochemistry tests46-48. However, these 
measures only identify progressive disease rather than predict progression. Given the similarities 
between HIV and FIV, similar monitoring techniques may allow identification of immune 
activation and prediction of progression to clinical disease in FIV-infected cats. This could result 
in earlier medical intervention to prevent or slow progression to symptomatic infection and 
extend good quality of life. As the shelter industry moves to adopt rather than euthanize FIV-
infected cats, there is an emerging population of FIV-infected cats in shelters. Monitoring 
techniques that can assess immune health and predict progression to symptomatic infection may 
help improve the care and management of FIV-infected shelter cats and improve adoption rates 
by providing a better health assessment to potential adopters. 
This review provides a general overview of epidemiology, transmission, diagnosis and course of 
FIV infection. It addresses mechanisms of cellular infection, virus dissemination and immune 
impairment including histopathologic alternations secondary to infection and compares FIV to 
human immunodeficiency virus (HIV). A summary of future directions for patient monitoring 





2.2 Feline Immunodeficiency Virus 
Feline immunodeficiency virus is a lentivirus in the family Retroviridae. This group of viruses 
uses reverse transcriptase to make a double stranded DNA (dsDNA) copy of viral RNA and insert 
it into the host cell genome. Insertion into the host genome allows for transmission of the virus to 
daughter cells during cell division and propagates life-long infection49,50. Lentiviruses, including 
FIV, HIV and SIV, have similar genes including env, gag and pol49. The proteins encoded by 
these genes have specific functions that allow for replication and survival within the host. The env 
gene encodes for envelope proteins associated with attachment, fusion and infection of target 
cells. This region is the most variable and is prone to mutation or recombination events that help 
the virus evade the immune system in circulation. The gag gene encodes the structural proteins of 
the virus and is less prone to mutation and recombination. The pol gene encodes the 
transcriptional proteins, most notably reverse transcriptase, and is the most conserved allowing 
for successful replication and integration of new viral DNA into the host genome49,50. 
Several FIV subtypes exist based on phylogenetic mapping of these three genetic regions and are 
identified as A through F51-56. FIV has a worldwide distribution and the most prevalent subtype 
varies by location. Subtypes A and B have the broadest worldwide distribution. Subtype C is rare 
in the United States but prevalent in Australia and Canada57,58. Subtype D is reported in Japan and 
Vietnam, and subtype E is found in Argentina55,56. Subtype F, thought to be a variant of subtype 
B, has only been identified in the United States51,52. Based largely on experimental infection, 
using differing strains and infecting doses of FIV in kittens and cats of varying ages, there appear 
to be differences in subtype pathogenicity. These experimental observations on subtype 
pathogenicity have not been reported in naturally acquired FIV infection of domestic cats. In 
general, subtype B is believed to be the least pathogenic, resulting in the mildest clinical signs 
and longest time to disease progression54. This subtype is also more genetically diverse and may 
show the most host adaptation based on studies of wild cat populations54,59. Subtype C has been 
reported as the most virulent and pathogenic strain resulting in rapid disease progression and 
death60. Subtype A has moderate pathogenicity and may be more associated with the development 
of neurological disease signs than other subtypes54. 
Commonly, subtyping of FIV has been performed using the variable regions 3 through 5 (V3-V5) 
of the env genes however, use of the gag and pol genes has also been performed and similar 
subtyping results are reported between genes57. Diversity within the V3-V5 env regions of 
subtypes A, B and C has been reported to be 3-15% within a subtype and 18-26% between 
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subtypes53. The env gene encodes for the outer surface glycoprotein of the virus and is 
responsible for attachment and entry of the virus into the cell; therefore it is easily detected by 
immune surveillance cells and serves as the primary target for antibody production. As a result, 
the env gene is under pressure to evade the immune system. One such protective mechanism is 
recombination which results from crossover between viral genomic RNA regions within the 
host57. Recombinant events between 2 strains of the same subtype can occur as either intragenic 
or intergenic recombination57. Intragenic recombination results from crossover between 2 single 
gene regions whereas intergenic recombination results from crossover between 2 different gene 
regions57. In a recent study, recombination events in the env region occurred in 41% of the 
naturally infected cats that were studied61. In a separate but related study, an evolutionary rate of 
1.16 x 10-3 substitutions per site per year was reported in naturally FIV-infected cats, which is 
faster than 3.1-6.6x10-3 rates previously reported57,62,63. The rate of viral evolution was found to 
be higher in those cats without physical examination abnormalities as compared to those without 
which suggests increased pressure for viral evasion of the immune system in healthy FIV-infected 
cats62. 
Recombination may also occur when 2 different parent viral strains are present within the host 
either due to co-infection or super-infection57,64. Co-infection, as defined for HIV, results from 
recent infection with a second viral strain before the first viral strain infection has been 
established and an immune response developed. Super-infection results when the second viral 
strain infection occurs after the first viral strain infection was established and an immune 
response developed64. The existence of co-infection and super-infection, in both HIV and FIV, 
can be difficult to determine in natural infection but the occurrence of phenotypes displaying 
sequences of multiple subtypes has been reported. In FIV infection, recombination events 
between A/B, B/D and A/C subtypes have been reported54,65,66. 
2.3 Epidemiology and Transmission 
Seroprevalence for FIV antibodies in various countries has been reported to be between 2% and 
34%1-14. Variability in seroprevalence is attributed to several factors such as whether cats studied 
are owned, stray or feral, are allowed to roam outdoors or display clinical signs of illness at the 
time of testing. A recent study in Germany reported the seroprevalence of FIV to be 3.2% in a 
group of healthy privately owned cats brought to the veterinarian for routine healthcare6. A study 
in Egypt reported the seroprevalence of FIV to be 33.9% in a group of feral cats captured as part 
of a trap-neuter-release effort2. Two other studies, from Japan and Malaysia, reported the 
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seroprevalence of FIV in healthy cats, with access to the outdoors, to be 4.2% and 23.6%, 
respectively3,9. The latter two studies reported a higher seroprevalence of FIV (18.8% and 38.4%, 
respectively) in cats identified as unhealthy at the time of testing3,9. In the United States and 
Canada, the overall seroprevalence of FIV is estimated to be approximately 2.5% and 5.5%, 
respectively, in domestic cats. A higher prevalence has been reported in cats allowed outdoors 
(4.3%), cats in large sanctuaries (8.8%) and cats presented to veterinarians with clinical signs of 
illness (up to 20.6%)14,15,67. 
Transmission is reported to occur most commonly through saliva exposure via deep penetrating 
bite wounds. Adult, intact, outdoor male cats are reported to be at increased risk due to territorial 
fighting behavior1,3,13,14,68,69. There was no reported horizontal transmission of infection in 
households where FIV-infected and FIV-uninfected cats comingle, are kept strictly indoors, not 
introduced to new cats, and have minimal inter-cat aggression3,6,70,71. Parenteral injection 
(intravenous or intraperitoneal) of FIV-contaminated tissue establishes infection, however, this is 
considered an unlikely route of naturally acquired infection46,72-76. Transmission during mating 
appears possible as virus has been detected in feline seminal fluid but this is not thought to be a 
common transmission pathway72-76. 
Transmission from queen to kitten is reported in experimental infection and infection rates may 
be as high as 70% but this appears to be uncommon in naturally acquired infection77. In 
experimental settings, transmission from queen to kittens can occur in utero, during parturition 
with exposure to vaginal secretions and via colostrum and milk78-81. FIV-infected queens have a 
higher rate of abortion, stillbirth and nonviable kitten delivery78,82. The rate of transmission 
during pregnancy seems to be higher in FIV-naïve queens infected during pregnancy and 
chronically FIV-infected queens with low CD4 T cell counts (<200cells/uL)79. Kittens born to 
FIV-infected queens may test FIV-positive by virus isolation (VI) and polymerase chain reaction 
(PCR) at birth and by antibody titer as early as 2 weeks of age78,82. In experimental settings, some 
kittens have shown evidence of regressive infection after testing FIV-positive by VI, PCR and 
antibody test82. In regressive infection, there is a loss of detectable FIV antibody, virus and 
provirus in peripheral blood despite having tested positive at earlier time points. However it is not 
known if these kittens have truly cleared the virus or if disease remains in tissues at an 
undetectable level or latent state78,82. Similar events have been reported for HIV in perinatally 
infected children but again, it is not known whether the virus remains in the tissues or has been 
cleared from the body83. 
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2.4 Cellular Infection and Dissemination 
2.4.1 Cellular Infection 
In FIV, similar to HIV and SIV, CD4 T cells are the primary target for infection during acute 
infection and throughout the course of disease. The CD4 T cells are a key component of the 
adaptive immune system and function to direct the humoral (antibody production) and cell 
mediated (cell-to-cell interactions) arms of the immune system84. During the chronic phase of 
infection, FIV infects macrophages, neutrophils and dendritic cells within the innate immune 
system. These cells are considered generalized surveillance cells, are the first line of defense 
against infection, and activate the adaptive immune response. 
Similar to HIV, FIV requires a co-stimulatory signal in order to infect an individual cell. FIV 
utilizes CD134 and CXCR4 receptors on T cells for cell entry32,49. The FIV glycoprotein 120 
subunit (gp120), encoded on the V3 loop of env, first binds to the CD134 receptor on the 
activated host T cell. This induces a conformational change exposing a cryptic epitope in the V3 
loop to allow binding to the CXCR4 receptor, which is the necessary co-stimulatory signal to 
allow the virus to gain entry into the cell32,49,85. Once this attachment is complete the virus fuses 
with the host cell membrane and the virus particle is brought into the cell. 
CD134 is expressed at higher concentrations on activated lymphocytes, in particular CD4 T cells, 
which are the primary target cell for FIV infection85. CD134 is also found on activated CD8 T 
cells, B cells and monocytes/macrophages85. The chemokine, CXCR4, is found on all cells but is 
expressed in higher concentration on monocytes and macrophages. These receptor location and 
concentration distinctions help explain the pattern of cellular infection. Host CD4 T cells are the 
primary targets but as chronic infection is established the target cell population expands to 
include CD8 T cells, B cells and monocytes. In one study, the shift in cellular infection from CD4 
T cells to monocytes and macrophages occurred with the appearance of clinical signs of disease86. 
This shift in cellular infection was thought to reflect the emergence of a viral variant that 
preferentially infected monocytes and macrophages87. Mutations in the env region of the virus 
during replication during experimental infection have been reported to produce a variant that is 
CD134-independent with an increased ability to infect cells lacking CD134 but expressing 
CXCR4 (i.e. monocytes and macrophages)85. The use of CD134 as a primary receptor for viral 
entry into a cell involves a complex interaction with the cysteine rich domains 1 and 2 (CRD1 
and CRD2) of the receptor but as infection progresses the interaction with the CRD2 region 
decreases and becomes less complex88. It has been suggested that in “early” FIV infection the 
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virus is CD134-dependent whereas in “late” infection the virus is CD134-independent. It has been 
reported that removal of a single glycosylation site in the V1-V2 viral homolog contributes to the 
shift away from CD134 dependence for viral entry89. Recently it was reported that a higher 
proportion of CD134-independent viral variants was associated with an increase in abnormalities 
on physical examination, CD4 T cell counts <350 cells/µL, and death suggesting that a shift 
towards these viral variants are associated with disease progression88. 
Once inside the cell, the FIV virus makes a double stranded DNA (dsDNA) copy of its viral 
RNA, utilizing reverse transcriptase (RT). Creation of dsDNA from viral RNA involves a series 
of events: 1) RT creates a strand of complementary DNA (cDNA) of the RNA genome, 2) RNase 
H activity removes the RNA strand from the cDNA strand, 3) the cDNA anneals with the end of 
another viral RNA strand and polymerization of DNA continues, 4) the annealed RNA is 
degraded in multiple areas by RNase H, 5) another strand of DNA is created using the remaining 
segments of RNA as a primer, 6) the DNA strands are separated and 7) the newly formed DNA 
strand anneals to a different DNA strand to create a complete double stranded DNA (dsDNA). 
Once complete, this dsDNA copy is inserted into the host genome in the nucleus of the cell. 
The dsDNA is transported to the nucleus as part of the pre-integration complex (PIC) and 
interacts with FIV integrase to tether it to the host cell chromatin. Integration of the dsDNA 
occurs through cleavage, repair and ligation of the new dsDNA to the host target DNA to create a 
new genome sequence49,90. The insertion of the dsDNA copy into the host genome ensures the 
viral material will be passed to daughter cells resulting in life-long infection. It also allows 
evasion of the immune system by disguising itself as part of the host cell genetic material49,90. 
Transcription of viral RNA copies within the nucleus and packaging of new virion particles 
within the cytoplasm is also performed. New virion particles are released to spread infection to 
new cells. It is thought that the accessory protein, OrfA, initiates transcription indirectly within 
the nucleus. Then Rev protein interacts with Rev-response element, both encoded within the 
virus, to shuttle target RNA out of the nucleus. Once outside the nucleus, proteins are translated 
from the genomic transcript and then identified and captured for packaging the gag proteins. The 
gag proteins provide the main structure of the virion and play a role in budding and release of the 
virion from cells, although the mechanism is not well understood. Tetherin, a transmembrane 
protein, anchors the virion to the cell and is thought to interfere with its release, however, with the 
CD134-independent strain of FIV, tetherin may actually enhance cell-to-cell spread of the virus 
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by syncytial formation. During maturation of the virion, viral protease cleaves several precursor 
polyproteins from Gag and Gag-Pol. These precursors are then further cleaved in specific order 
to form the mature virion and activate enzymes associated with its ability to infect a new cell. The 
release of new viral particles contributes to continued infection of naïve CD4 T cells, 
macrophages and dendritic cells and perpetuates a state of active infection49,50, 90. 
2.4.2 Dissemination 
Rapid and widespread dissemination of FIV occurs concurrently with the cellular alterations in 
peripheral blood and other tissues following experimental infection87. Proviral DNA can be 
detected in 1/1,000,000 circulating PBMC by day 5 post-infection and in 1/100,000 cells day 84 
post-infection87. Proviral DNA was isolated as early as 10 days post-infection from thymus, 
lymph nodes, tonsils, lungs and brain and several weeks later from peripheral lymph nodes, 
spleen, bone marrow, intestines and spinal cord87.  Viral RNA was detected in PBMC as early as 
14 days post-infection at a rate of 1/100,000 and this increased to 1/100 by 6-8 weeks post-
infection87. Similarly, virus was detected in plasma around 3 weeks post-infection and continued 
to increase until approximately 6-8 weeks post-infection before rapidly falling to low or 
undetectable levels (typically associated with asymptomatic disease)22,87,91. At this stage, viral 
RNA is found in approximately 1/1000 peripheral blood mononuclear cells (PBMC) 87. This rise 
and fall in viremia and PBMC infection coincided with the appearance and resolution of clinical 
signs of illness seen 6-8 weeks post-infection and with a decrease in CD4 T cells and expansion 
of CD8βlow cells within lymph nodes and peripheral blood. This shift in viral RNA (free virus) to 
viral DNA (provirus) is indicative of the ability of the immune system to control but not clear 
infection87. 
Humoral immunity as measured by non-neutralizing or binding antibody production by activation 
of B cells to the p24 viral capsid protein was reported as early as 2 weeks following experimental 
infection87. This antibody response peaked about 6-8 weeks post-infection prior to the decrease in 
viremia and remained detectable life-long87,92. Production of FIV antibodies is aimed primarily at 
the V3 regions of the env gene due to its role in attachment of the virion to the cell but also the 
V4 and V5 regions93. As protection against the immune system, the env region is coated in N-
glycosylation sites (carbohydrates that are linked to viral proteins) that mask the epitopes 
responsible for entry into the cell93. Non-neutralizing antibodies, which bind to viral epitopes 
exposed on the outer membrane of the virion, flag the antigens for destruction by immune cells 
but do not inhibit their infective capabilities. This is in contrast to neutralizing antibodies that 
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bind to viral epitopes and block infection by interfering with binding of the virion to its receptors, 
blocking virion uptake into a cell, preventing uncoating of the viral genome within a cell or 
causing aggregation of viral particles in circulation84. In FIV, similar to HIV, neutralizing 
antibodies develop slowly over time and have been reported to plateau at 50-60% neutralization 
ability at 4 years post-infection93,94. Broad neutralizing antibody activity, or the ability to 
neutralize multiple viral strains, is considered rare. In a recent study including 345 plasma 
samples from FIV-infected cats, detection of broadly neutralizing antibodies against a 
representative FIV subtype A (GL8) ranged from 0-100%; however, only 2 of 345 plasma 
samples from FIV-infected cats had broad neutralizing ability against a range of infectious 
subtype strains of FIV93. This suggests that humoral immunity does not play a strong role in 
combating the spread of infection to new cells. 
2.5 Mechanisms of Immune Impairment 
In uninfected healthy adult cats, CD4 and CD8 T cell counts have been reported as 1182 cells/µL 
(range: 543-1820) and 674 cells/µL (range: 353-994), respectively, with a CD4:CD8 ratio of 1.9 
(range: 1.2-2.6) 95. Following experimental infection, alterations within peripheral blood, 
lymphoid and non-lymphoid tissues are well characterized. Within the first 6-8 weeks of infection 
there is a marked decrease in CD4 T cell counts, commonly below the reference interval. CD4 T 
cell levels have been reported to be as low as 20% of pre-infection levels at the peak of clinical 
signs of illness86. Infected CD4 T cells are removed by direct cell-to-cell interaction with 
cytotoxic CD8 T cells. Apoptotic pathways (programmed cell death secondary to infection) are 
activated secondary to cellular infection and cell lysis secondary to rupture and release of new 
viral particles also serve to decrease CD4 T cell populations84. CD8 T cell counts also decline, but 
to a lesser extent 96. CD4 T cell counts may recover during the asymptomatic phase, but not to 
pre-infection levels and in chronic infection this decrease in CD4 T cells typically does not 
become statistically significant until about 18 months after infection20,97. In one study of 
experimental infection, the mean CD4 T cell count was reported as 691±130 cells/mm3 in FIV-
infected cats compared to 1450±46 cells/mm3 in FIV-uninfected cats at 18 months post-
infection98. 
There is an overall inversion of the CD4:CD8 ratio throughout the remaining course of 
infection20,22,23,99. In one study, 2 experimentally infected cats were reported to have CD4:CD8 
ratios of 0.62 and 0.49 at 103 weeks post-infection23. In a recent study of experimentally infected 
cats, the CD4:CD8 ratio inversion was reported to be statistically significant as soon as 6 weeks 
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post-infection and averaged 0.75±0.47 in chronically FIV-infected cats compared to 1.65±0.38 in 
FIV-uninfected cats22.  Loss of CD4 T cells and decline of CD4:CD8 ratios are hallmarks of FIV 
infection. A subset of CD8 T cells (CD8βlow) increases in FIV-infected cats compared to 
uninfected cats98,100. The expansion of  CD8βlow cells begins within weeks of infection and they 
comprise up to 90% of the total CD8 T cell population at ≥7 years post-infection100. In a set of 
experimentally infected cats, CD8βlow cells comprised 2.98 ± 0.8% (174±14 cells/mm) of 
peripheral blood mononuclear cells pre-infection compared to 17.31 ± 9.5% (1120±30 cells/mm) 
post-infection98. Absolute CD8βlow  cell count  at 18 months post-infection has been reported to 
be 352 ± 60 cells/mm3 in FIV-infected cats compared to 158 ± 60 cells/mm3 in FIV-uninfected 
cats98. The CD8βlow cells are considered activated effector cells as determined by the phenotype, 
CD8βlowCD62L-CD44+CD18+CD49+. This is similar to what occurs in HIV-infected people101. 
CD8βlow cells suppress viral replication in vitro and are thought to be responsible for decreasing 
viremia in acute infection and maintaining low level viremia during asymptomatic infection in 
FIV-infected cats102,103. The exact mechanism of action is not known but the presence of 
CD8βlow cells in culture with FIV-infected cells greatly reduced viral replication within cell 
culture supernatant104. Presumably this is done through cell-mediated immunity mechanisms that 
may include direct interaction with cytotoxic T lymphocytes (CD8 T cells) and production of 
cytokines (interferon-gamma and tumor necrosis factor) that protect cells against viral 
infection 105. 
Cats that progress to the terminal stage of illness may exhibit marked immunosuppression and a 
lack of response to FIV viral replication and invasion by secondary pathogens106. During end 
stage disease a decline in FIV antibody production to undetectable levels, a resurgence in viremia, 
severe loss of CD4 T cells, and markedly decreased CD4:CD8 ratio have been reported compared 
to cats in the asymptomatic stage of infection18,19,24,107 . In studies of naturally infected cats, viral 
loads were reported to increase 100-150 fold compared to cats in the asymptomatic stage of 
disease24,107. Significant declines in CD4 T cells (671±432 vs 147 ±103 cells/µL), CD8 T cells 
(492±314 vs 162±72 cells/µL) and CD4:CD8 ratio (1.45±0.53 vs 0.87±0.26) in cats in the 
asymptomatic stage of infection compared to cats in end stage infection have been reported24. In 
one study of experimental FIV infection, the most severe decline in reported for a cat in end stage 
disease was a CD4 T cell count of 21 cells/µL and a CD4:CD8 ratio of 0.075108. However, in 
another study of experimental infection, one cat in the chronic stage of infection had a CD4 T cell 
count of 42cells/µL and had no clinical signs of illness. This suggests that some cats may be able 
to tolerate low CD4 T cell counts without adverse side effects. Acute and chronic FIV infection 
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has been widely studied but the long duration of infection, particularly the lengthy asymptomatic 
stage of infection, makes longitudinal studies of infected cats reaching end stage disease difficult 
and expensive. Additionally, it is unknown what percentage of cats will progress to end stage 
disease and recent reports have indicated FIV-infected cats may likely succumb to other diseases 
before they succumb to FIV infection14,67,68. As such, the underlying factors that cause 
progression from asymptomatic to end stage disease remain elusive. 
The underlying immune dysfunction in FIV-infected cats is reported to be the result of alterations 
in T cell populations, lymphoid tissue structure, cytokine production and immune responses to 
pathogens. However, the underlying cause of immune dysregulation and disease progression has 
yet to be defined. Several mechanisms have been suggested, including cytokine dysregulation, 
immunologic anergy, activation of immune regulatory cells and chronic immune activation109. 
Cytokines are secreted proteins that direct communication signals from one cell to another in 
order to direct an immune response. There are several classes of cytokines including: interleukins 
(communication signals between leukocytes), colony stimulating factors (support hematopoietic 
precursor proliferation), tumor necrosis factors (stimulates cytotoxicity) and interferons (interrupt 
viral replication)105. Cytokines are constitutively produced to help maintain immune homeostasis 
but are specifically up-regulated or down-regulated during an immune response. Kipar et al 
investigated the constitutive expression of several cytokines (interleukin-1β (IL-1β), IL-6, IL-10, 
IL12, and tumor necrosis factor-alpha (TNF-α)) from monocytes and macrophages in healthy cats 
over a range of ages (15 months to 10 years) and reported that all cytokines were constitutively 
expressed but this expression was variable within an individual cat and between cats of the same 
age. In general, the highest transcription levels were found in young adults and older cats for IL-
1β, IL-6 and IL-12 whereas transcription levels of IL-10 and TNFα remained stable across 
different ages110. 
FIV infection alters cytokine production and response to various infections. Monocyte and 
macrophage constitutive cytokine transcription levels in experimentally asymptomatic FIV-
infected cats were decreased compared to uninfected controls with only IL-1β found in all FIV-
infected samples111. Alternatively, the PBMC transcription of these cytokines is markedly 
increased in symptomatic infection compared to asymptomatic infection112-116. In one study of 
FIV, the mRNA levels of interleukin 10 (IL-10) and interferon-gamma (IFNγ) from PBMC were 
highest at 6-8 weeks post-infection, with a transient peak in IL-4. This correlated with the 
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presence of clinical signs of acute infection. The mRNA cytokine levels then decreased, although 
not to the level of pre-infection, once the cats entered the asymptomatic phase. The CD4 T cells 
appeared to be the main source of IL-2, IL-4, IL-10, IL-12 transcription, and CD8 T cells were 
the main source of IFN-γ transcription113. In chronic FIV infection, both experimentally induced 
and naturally acquired, infected cats had increased plasma levels of IL-1β, IL-6 and TNF-α and 
had decreased IL-2 production and decreased PBMC proliferation in response to mitogen 
stimulation compared to uninfected cats112. The altered cytokine production and mitogen 
responses were more pronounced in symptomatic cats with clinical signs of illness (anorexia, 
weight loss, fever, stomatitis, lymphadenopathy, anemia, leukopenia and hyperglobulinemia) 
compared to asymptomatic FIV-infected cats112. When challenged with intracellular pathogens 
such as Toxoplasma gondii and Listeria monocytogenes, FIV-infected cats had less lymph node 
enlargement, broader pathogen dissemination, higher pathogen burden and decreased 
inflammatory cytokine production, all consistent with an increased susceptibility to infection and 
a decreased ability to clear infection compared to uninfected cats113,114. The alterations in cytokine 
production resulted in an increased IL-10:IL-12 ratio which may represent a cytokine shift in 
FIV-infected cats that favors a Th2 humoral immune response over a Th1 cell mediated response. 
This could contribute to impaired ability to quickly clear infection via cell-to-cell interaction and 
cytotoxic mechanisms113,114,116. A similar cytokine profile has been identified in HIV-infected 
people, including high pro-inflammatory cytokines INF-α, IL-1, IL-6, IL-18 and TNF-α, and is 
associated with innate immune cell activation, apoptosis of immune cells, and decreased 
lymphocytes levels that in turn decreases homeostatic cytokine production (IL-17, IL-22) from 
lymphocytes117,118. 
Initiation of an adaptive immune response is dependent on interaction with cells of the innate 
immune system. During this interaction an antigen presenting cell (APC), typically a dendritic 
cell or macrophage, bearing an epitope of the invading antigen binds to the T-cell receptor (TCR) 
specific for that epitope on a naïve T cell. Once bound to the T cell, a costimulatory signal 
between the APC and T cell is needed to direct the cell’s immune response. In general, this 
costimulatory signal either propagates or dampens the inflammatory immune response. In every 
immune reaction both responses are needed – one to increase the immune response to clear the 
infection and the other to regulate the immune response to avoid unnecessary and prolonged 
tissue injury. In the pro-inflammatory response, B7.1 or B7.2 (CD80 and CD86, respectively) on 
the APC binds to CD28 on the T cell to initiate signal transduction and inflammatory cytokine 
production to direct humoral and/or cell-mediated immunity84,105. This co-stimulation causes 
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increased production and release of IL-2, up-regulation of IL-2 receptors, and activation of 
neighboring T cells to increase the response to the pathogen threat. In contrast, during the 
regulatory response, B7.1 or B7.2 on the APC binds to cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) on the T cell to induce a state of anergy (inactivity) or activate apoptosis. 
This reaction causes decreased IL-2 production and down-regulation of IL-2 receptor expression 
which eliminates the activation signal to neighboring T cells. Up-regulation of CTLA-4 on the T 
cell usually occurs 2 to 3 days after the initiation of the T cell immune response. Cellular anergy 
and apoptosis are important and necessary steps in regulating the immune response. Binding 
affinity of B7 to CTLA-4 has been reported to be 20-100X that of CD28 suggesting the 
importance of the regulatory response84,105. Several studies have reported that lymphocytes from 
lymph nodes and peripheral blood of FIV-infected cats have increased expression of B7.1, B7.2 
and CTLA-4 and decreased expression of CD28 compared to those from uninfected cats119-122. 
These changes in expression patterns of CD4 and CD8 T cells have been reported to increase with 
age and time post-infection and are inversely correlated with lymph node CD4:CD8 ratio and 
peripheral CD4 and CD8 T cell counts121. Additionally, after 24 hours in culture, T cells from 
FIV-infected cats showed increased levels of spontaneous apoptosis compared to those of 
uninfected cats, particularly after stimulation with Concanavalin A119-122. The level of 
spontaneous apoptosis and anergy in stimulated cultured T cells can be decreased by either 
addition of exogenous IL-2 or antibody blockade of B7 and CTLA-4 receptors, particularly B7.1, 
although reduction of apoptosis is not complete119,122. A better response to apoptosis blockade has 
been reported in FIV-infected cats with viral RNA loads <1x10⁵ compared to FIV-infected cats 
with higher viral RNA loads119. Based on the up-regulated expression of B7.1 and B7.2, it has 
been shown that activated T cells can act as APC and mediate apoptosis and anergy through T 
cell-T cell interactions between B7 and CTLA-4 binding122. 
Regulatory T cells (Treg) are a specific subset of CD4 T cells that carry the activated phenotype 
CD4+CD25+CTLA4+ and are differentiated in the presence of TBGFβ and IL-6 using the 
transcription factor FoxP3123-125. These cells constitute about 5-10% of T cells in peripheral blood 
and 20-30% of T cells in lymph nodes in both FIV-infected and uninfected cats. Treg cells have 
increased activity in FIV-infected cats123, in both the acute and chronic states of infection, 
compared to FIV-uninfected cats and decrease the immune response to invading pathogens, 
however, the exact mechanism of increased activity is unknown122. It is known that once 
activated, these cells do not produce the cytokine IL-2 or up-regulate IL-2 receptors on the cell 
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surface and therefore fail to activate surrounding CD4 T cells to produce an appropriate immune 
response123. In culture, these cells have been reported to suppress the immune system by cell-cell 
interaction and down-regulate IL-2 production and receptor expression in neighboring T cells123. 
Chronic immune activation (immune hyper-activation) has been shown to occur in CD4 and CD8 
T cell populations of FIV-infected cats. Phenotypic analysis of activation in the T cell populations 
of FIV-infected cats has revealed decreased CD8β chain immunofluorescence, down-regulation 
of CD62 L-selectin on CD4 and CD8 T cells, progressive loss of the CD8 naïve cell pool, and up-
regulation of CD25100,101,121. These changes are consistent with the immunophenotype of a 
chronically activated immune system. Studies show that up to 70% of CD8 T cells and 80% of 
CD4 T cells have an activated phenotype in cats infected with FIV ≥7 years98,100,101. In addition to 
T cell hyper-activation, chronic B cell activation has also been reported in FIV-infected cats; this 
results in a polyclonal hypergammapathy secondary to increased antibody production20,126. The 
role that immune hyper-activation may play in disease progression has not yet been defined. 
Together these changes in chronically FIV-infected cats – altered cytokine production, increased 
cell anergy and apoptosis, immunosuppression secondary to increased Treg activation and a state 
of immune hyper-activation – all contribute to an altered immune response and place the cats at 
increased risk for clinical disease. 
2.6 Course of Infection 
The course of FIV infection includes an acute phase followed by a long period of chronic 
infection during which progression from an asymptomatic to symptomatic state of infection is 
expected. In the acute phase of infection cats may experience transient signs of clinical illness. In 
experimental studies, lymphadenomegaly is reported as early as 10 days post-infection and may 
persist for months22,69,86,112,127. Further clinical signs of acute disease such as fever, diarrhea, 
malaise, anorexia and dehydration may occur approximately 6 weeks post-infection, with some 
cats requiring fluid support and antibiotic therapy33,86,99,127. These vague clinical signs may go 
unnoticed by the pet owner  
As transient clinical signs resolve, cats enter an asymptomatic phase of infection. This 
asymptomatic phase can lasts months to years before progressing to a symptomatic phase of 
infection22,69,97,127. The symptomatic phase of infection is characterized by varied clinical signs 
including, but not limited to, diarrhea, stomatitis, periodontitis, gingivitis, upper respiratory 
infection, and other opportunistic infections92,127,128. During this period of symptomatic infection 
cats often respond to supportive therapy and antibiotic treatment and may transition between 
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asymptomatic and symptomatic states. Many of these cats eventually progress to end stage 
disease marked by weight loss, loss of body condition, generalized muscle wasting, lymphopenia, 
neutropenia, anemia, and / or bacterial, viral and fungal infections that are refractory to treatment 
or opportunistic17,19,33,41,112,129,130. Neoplasia, most commonly lymphoma, but also squamous cell 
carcinoma, myeloproliferative disease and fibrosarcoma are reported to occur at a higher 
incidence in FIV-infected cats131. Lymphoma has been the most commonly reported neoplasia in 
FIV infection and although a direct mechanism has not been identified it is suspected that viral 
interruption or transformation of the host cell cycle oncogenes or tumor suppressor genes is 
involved17,92,131,132. 
While the general disease course is similar among cats, course of disease and clinical signs seen 
differ between individual cats and between study groups. Age at the time of infection is thought 
to play a role in disease progression as neonatal kittens are reported to suffer more severe blood 
dyscrasias (neutropenia, leukopenia) and prolonged lymphadenopathy in the acute phase while 
aged cats appear to have delayed antibody response, lower T-lymphocyte levels and more severe 
chronic illness than young adult cats or kittens133. The underlying cause of the delayed immune 
response in aged cats is not known but may be related to or influenced by the immunosenescence 
of aging. Differences in dose, strain, route of infection, initial immune response to infection, and 
immune competency at the time of infection may also influence the progression of disease. In 
naturally acquired infection, the infectious dose, FIV strain, and initial immune response to 
infection are unknown which makes extrapolation of experimental data difficult. However, in a 
recent study of experimental FIV infection, it was reported that within groups of cats given the 
same infectious dose of one of three viral strains there was a variety of immune responses. The 
variation in immune response was dose-dependent and positively correlated with viremia and 
CD8βlowCD62Lneg expansion over the first 12 weeks post-infection134. This supports previous 
findings that individual immune response to FIV infection was varied but appeared to be dose-
dependent as cats receiving a lower infectious dose had a longer time to seroconversion and 
undetectable lymphadenopathy as compared to those that received higher infectious doses135. 
These results suggest that infectious dose and initial immune response may predict disease 
progression but long term follow-up in experimental settings has not been performed. 
Experimental infection poses a unique situation in that FIV-infected cats are commonly housed 
under specific pathogen free (SPF) conditions which shield them from common pathogens that 
naturally FIV-infected cats may encounter. Similarly, housing conditions of naturally infected 
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cats may influence an individual cat’s immune status and response to pathogen exposure. 
Crowded housing conditions and shelter housing have been associated with increased upper 
respiratory infection136,137. These housing conditions also carry increased risk of intestinal and 
dermatophyte pathogen exposure if proper hygiene protocols are not implemented and 
followed138. In a recent study, it was reported that FIV-infected cats living in a large multi-cat 
household had more clinical signs of illness on examination and shorter survival times compared 
to FIV-infected cats living in private homes of less than 2 cats, this suggests that management and 
housing play a role in FIV disease progression139. 
2.7 Diagnosis 
Published guidelines recommend initial  FIV testing by commercially available in-house ELISA 
tests be done for any cat that is: 1) new to a household, 2) showing signs of clinical illness, 3) 
living in a high-risk environment (outdoor cats, dynamic household or living with FIV-infected 
cats), or 4) FIV-uninfected and recovering from a cat fight. Retesting is recommended at least 60 
days after an initial negative test in cats that are new to a household, have a recent history of 
fighting, after an initial positive test in kittens less than 6 months of age when maternal antibodies 
may still be circulating, or in cats with positive results and unknown history of FIV vaccination 
(which results in antibodies indistinguishable from those generated by natural infection). Annual 
testing is recommended for any FIV-uninfected cat living in a high-risk environment46-48 . 
Initial testing for FIV is typically performed using an in-house enzyme linked immunosorbent 
assay (ELISA) to detect antibody against FIV p24 surface protein. In the case of positive ELISA 
test results or high suspicion of disease in a cat with negative results, additional testing is 
recommended46,47. It is important to note that no diagnostic method for FIV is absolute therefore 
caution in interpretation of results is crucial. 
False positive ELISA results can occur secondary to maternal antibodies in kittens less than 6 
months of age, or in cats that have received an FIV vaccination. Available ELISA tests cannot 
differentiate between antibodies acquired via maternal transfer, antibodies secondary to 
vaccination, and antibodies secondary to active infection140,141. Cats which have received the FIV 
vaccine reportedly test antibody-positive on ELISAs for years following the last FIV 
vaccination141-143. In a recent study, it was FIV-uninfected cats that received the FIV vaccination 
tested antibody-positive on in-house ELISA tests as long as 11 years after the last FIV 
vaccination was given (Nichols et al, unpublished data). False negative ELISA results, although 
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less common, can occur early in infection prior to seroconversion, or in cats with end-stage FIV 
disease in which antibody production can be below a detectable level 144,145. 
Polymerase chain reaction (PCR) tests available commercially differ by primer set and reaction 
protocol, and reported sensitivity and specificity vary146,147. PCR tests detect the presence of viral 
RNA and DNA and can detect acute infection prior to the development of an antibody response. 
False positive PCR results can occur, for example, secondary to contamination at the time of 
sample collection or during processing at the laboratory. False negative PCR results can occur, 
for example, in cats with viral loads below that which can be detected by PCR. Detection limit is 
defined as the lowest number of viral copies that can be identified in a standard sample; detection 
limits vary between laboratories but can be as low as 1 to 10 copies in a given sample. 
Additionally, as primer sets and protocols differ between laboratories it is possible that a specific 
primer set will not detect all FIV strains. One PCR comparison study, between 3 different 
laboratories, reported sensitivities between 41 and 93% and specificities between 81 and 100% in 
correctly identifying cats infected with FIV subtypes A, B and C from those not infected147. 
Another study, using 3 different laboratories in Canada, found similar varied results146. Potential 
reasons for variation in reported sensitivities and specificities included sample contamination 
during sample processing, differing primer sets, detection limits and sample type (whole blood, 
plasma, serum or blood smear)143,146,147. 
Western blot serologic testing has been used as a confirmatory test for FIV infection. In this test, 
FIV core viral proteins, namely p24 and p15, are separated by size using gel electrophoresis and 
transferred to a membrane. The membrane is then incubated with a serum sample and a secondary 
fluorescent reagent to detect binding between viral proteins and sample antibodies. Binding of at 
least 2 separate viral proteins is needed to report a sample as positive; binding of only 1 protein is 
considered indeterminate143. Reported sensitivity and specificity are typically lower than those of 
ELISA tests144,146. False negatives can occur due to viral protein multimeric binding which creates 
viral proteins of larger size that will not be correctly identified as FIV viral core proteins143. 
Similar to other serologic testing, if the test is performed prior to an adequate antibody response a 
negative result may occur143. 
Virus isolation (VI) is considered the reference standard. Peripheral blood mononuclear cells 
(PBMC) isolated from FIV-infected cats are cultured with primary lymphoblast cells from SPF 
uninfected cats to determine whether infection is propagated from the PBMC cells to the blast 
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cells. Cultures are monitored for cell viability, cytopathic effect (ballooning degeneration, 
syncytium formation, and increased cell death), and Mg2+-dependent reverse transcriptase activity 
in the culture supernatant. A reaction is considered positive when there is a five-fold increase of 
reverse transcriptase activity in the culture supernatant of 2 consecutive samples as compared to 
negative control culture supernatant. Identification of the virus in supernatant by electron 
microscopy, antigen ELISA or IFA can be done148,149. 
Virus isolation can be falsely negative as the test is technically challenging to perform and the 
outcome of the test is largely based on viral activity over time making the duration of culturing 
time crucial. Similar to PCR, false positive results may occur secondary to sample contamination. 
False negative results may be due to several factors that influence duration of the procedure 
including: 1) circulating virus numbers, 2) the reverse transcription (RT) activity within a culture, 
3) viability of the virus and cells sampled from the infected cat, and 4) proper condition and 
maintenance of the culture cells and supernatant. Cats with high viral load would be expected to 
have a positive virus culture result sooner than cats with low viral load. The level of reverse 
transcriptase activity can also influence the speed at which VI may yield a positive result as 
increased RT activity would be identified sooner. Therefore, it is recommended that cultures be 
grown for 5 to 6 weeks before they are declared negative148. 
2.8 Hematology and Histopathology Alterations Secondary to Infection 
2.8.1 Hematology 
Hematological and serum biochemical alterations have been noted in FIV-infected cats. These 
alterations can fluctuate over time depending on other factors such as concurrent illness, 
environmental stressors, and age. Information regarding hematologic alterations in acute infection 
has largely been gleaned from experimental infection and in general, cats have leukopenia, 
neutropenia and sometimes lymphopenia as these cells respond to initial infection. Neutropenia is 
most likely to occur during acute infection as neutrophils are lost from circulation through 
diapedesis into tissues to respond to FIV-related inflammation20,22,33,150. Lymphopenia is the result 
of apoptosis and destruction of infected CD4 T lymphocytes following infection. In either natural 
or experimental infection, during the asymptomatic phase, FIV-infected cats may have lower 
mean leukocyte counts compared to FIV-uninfected cats but FIV-infected cats do not generally 
have a true leukopenia; cell counts remain within the reference interval but at the lower limit20,22. 
During the symptomatic phase, particularly end stage disease, marked anemia, leukopenia and 
thrombocytopenia may occur18,19,150. In either setting, serum biochemistry abnormalities most 
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commonly include hyperproteinemia attributed to a polyclonal hypergammaglobulinemia, 
thought to occur secondary to B cell stimulation and antibody production to varied FIV 
epitopes 20,68,69. Mild hypernatremia has also been reported but the underlying cause remains 
unknown68. Decreased urine specific gravity (USG) has been reported in naturally and 
experimentally infected cats without concurrent azotemia151. Additionally, naturally infected cats 
were reported to have a higher urine-to-creatinine (UPC) ratio compared to client-owned 
uninfected cats whereas experimentally infected cats had an increased creatinine level compared 
to SPF housed cats151. The reason for the difference between naturally and experimentally 
infected cats is unknown. 
2.8.2 Histopathology 
Histologic changes within lymph nodes, thymus, spleen, bone marrow, gut-associated lymphoid 
tissue (GALT), intestinal epithelium, kidneys, and brain have been reported. Alteration and 
compromise of structural integrity of these organs, particularly lymphoid organs, are seen as early 
as 3 weeks post-infection86,87. 
In experimental infection, the most severe lesions appear in lymphoid tissues at approximately 6-
8 weeks post-infection and coordinate with the appearance of clinical signs86. Changes are most 
dramatic in thymus, bone marrow, lymph nodes, spleen and mucosal associated lymphoid tissue 
(MALT) 86,87. Grossly, lymph nodes are enlarged and the thymus may be smaller in size 
compared to similar tissues in uninfected cats. Histologically, the thymus shows cortical 
involution, decreased thymocyte numbers and thymitis characterized by infiltration of 
lymphocytes and macrophages into the interlobular area86,87. The bone marrow is hyperplastic 
with increased cellularity characterized by increased granulocyte and monocyte precursors 
although the myeloid:erythroid ratio remains normal86,87 150. In peripheral lymphoid tissues, a 
progressive hyperplastic change is characterized by increased number and size of lymphoid 
follicles, prominent germinal centers, prominent high endothelial vessels (HEV) containing 
lymphocytes and expansion of parafollicular domains that contain lymphocytes, macrophages and 
lymphoblasts86,87. Similar findings are reported in adult cats naturally infected with FIV28. 
Histologically, lymph nodes show follicular hyperplasia but also follicular involution (cortical 
sinus collapse, small to non-existent germinal centers and eosinophilic hyaline deposits) or a 
mixture of both28. These central and peripheral lymphoid tissue histological findings are similar 
to those reported in people with chronic HIV infection. 
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Changes occur in other tissues. The histologic lesion most commonly reported is a perivascular 
inflammatory infiltrate, comprised of lymphocytes, neutrophils, plasma cells and macrophages in 
the small and large intestines, oral cavity, kidney, liver, lung, eyes and brain. Small intestinal 
villous blunting, loss of villi, crypt dilatation, and necrotizing enteritis is reported28. Additional 
secondary pathogens within the intestinal tissue that may be, in part, responsible for these lesions 
have not been identified28. Amyloid deposition in the organs of cats naturally infected with FIV 
has been reported in some naturally infected cats, but this is not reported in experimentally 
infected cats do not. A specific cause for this discrepancy is not known152,153. Renal amyloidosis 
is reported in HIV infection and, although considered uncommon, may be a contributing factor to 
the increased incidence of renal disease in HIV-infected patients154. 
2.9 Monitoring and Therapy 
Current recommendations for monitoring of cats infected with FIV include twice yearly physical 
examination and once yearly routine hematological and serum biochemistry panels and 
urinalysis46,47. These monitoring techniques identify illness and allow medical intervention only 
after disease has occurred. Currently, there are no readily available and reliable techniques to 
monitor FIV-infected cats to indicate progression of disease and when medical intervention 
should be initiated to prevent development of clinical disease. 
This is in stark contrast to the monitoring techniques and treatments available for HIV-infected 
people, for whom infection and disease progression has been traditionally monitored by 
measurement of CD4 T cell counts, viral loads, and evaluation of clinical signs. This information 
is used to decide when medical intervention is necessary and to gauge response to treatment34,35. 
The mainstay of HIV therapy is a combination of various anti-retroviral medications, known as 
highly active anti-retroviral therapy (HAART), tailored to the individual patient155. HAART 
therapy results in decreased viremia and increased CD4 T cell counts. The medications work by 
interrupting viral replication, at different stages, which reduces viral particle burden in tissues and 
peripheral blood. There are several points during viral replication at which antiretroviral therapy 
can interfere with replication including: 1) attachment of the virus to the host cell surface 
receptors, 2) fusion of the viral particle with the host cell, 3) reverse transcription of viral RNA, 
4) nuclear translocation and viral dsDNA integration, 4) nuclear export of viral mRNA, and 5) 
viral assembly and maturation of the virion in the cytoplasm. In HAART, the most commonly 
used class of drug is the nucleoside reverse transcription inhibitors (NRTIs). The general 
mechanism of these compounds is to generate altered deoxynucleotides (dNTs) that compete with 
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cellular dNTs for insertion into the elongating viral DNA strand. Once incorporated, these altered 
dNTs are unable to bind the next dNT in sequence and effectively halt production of that viral 
DNA strand. The first of these compounds to be approved for use in anti-retroviral therapy was 
azidothymidine (AZT) or Zidovudine. Since then, many other NRTI class drugs have been 
cleared for use in HIV-infected patients that each have slightly different mechanisms of action, 
reduced patient side effects such as anemia, and better tolerance of viral mutations50. 
Positive response to HAART therapy results in decreases provirus burden and increases CD4 T 
cells numbers in lymphoid tissues and peripheral blood of HIV-infected people. The decreased 
viral load lessens the burden of free virus that can infect new CD4 T cells which results in fewer 
CD4 T cells being removed by cytotoxic CD8 T cells and apoptosis, allows for restoration of the 
CD4 T cell count, and decreases the number of CD4 T cells acting as a reservoir of viral 
infection. The restoration of CD4 T cells, even though it may be incomplete, strengthens the 
ability of the adaptive immune system to respond to routine pathogen encounters in the mucosal 
tissues and within the lymph nodes. In most patients showing a positive response to HAART, 
there has been a significant increase in survival time and quality of life and a decrease in clinical 
signs of illness155 . There are some patients, though, that show progressive disease despite a 
positive response to HAART. In these patients, progressive disease and shorter survival times has 
been associated with increased immune activation rather than CD4 T cell counts or viral burden38. 
In FIV-infected cats several antiretroviral therapies have been investigated. Although two drugs 
have recommended doses for therapy, they have limited scope in use47. Zidovudine (AZT), the 
NRTI described above, is fairly well tolerated in cats and is effective in reducing clinical signs, 
decreasing viral burden and stabilizing CD4 T cell counts. However, in some cats it produces a 
non-regenerative anemia. Resistance to the drug is common and can occur as soon as 6 months 
after initiation. Drug resistance is secondary to the poor proof-reading and editing capabilities of 
FIV reverse transcriptase which allows for mutation of the viral genome and loss of the drug’s 
site of action. Another drug, AMD 3100 or Plerixafor, is a CXCR4 antagonist and blocks binding 
of the viral particle to the CXCR4 receptor. This prohibits fusion and entry of the virus particle 
into the host cell. The drug appears to be well tolerated in cats, results in a decrease in proviral 
load compared to a placebo, and does not show evidence of drug resistance. However, there were 
no reported significant decreases in clinical signs of disease in one study44. Other drugs that have 
been investigated, PMEA and D4API, have caused severe anemia or liver disease which in some 
cases was fatal45. 
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2.10 Microbial Translocation  
Microbial translocation is defined as the nonphysiological passage of gastrointestinal (GI) 
microflora through the intestinal epithelial barrier and lamina propria, with eventual 
dissemination to the mesenteric lymph nodes and then  extranodal, sites40. Microbial translocation 
is believed to have an important role in chronic immune activation of HIV-infected persons. 
When it became apparent that some HIV-infected persons still succumbed to progressive disease 
despite a positive, appropriate response to HAART, investigation showed that in some HIV-
infected persons, shorter survival times were not linked to increased viral burden or decreased 
CD4 T cell counts. Rather, these individuals had high levels of immune activation, as measured 
by markers of lymphocyte activation, and this immune activation better predicted progression of 
disease and a shorter survival time38. It was postulated that chronic immune activation led to 
immune exhaustion which in turn led to increased susceptibility to pathogens, enhanced other 
disease processes, and ultimately led to disease progression26,39. 
Brenchley et al.26,39 proposed that microbial translocation from the gastrointestinal tract into 
circulation as a source of chronic immune activation and disease progression as opposed to 
immune activation by HIV alone. In health, the gut associated lymphoid tissue (GALT) of the 
gastrointestinal tract (GIT) contains approximately 80% of the lymphoid tissue in the body, likely 
due to the constant exposure to microbial products at the interface of intestinal epithelial cell and 
luminal contents. Within the GIT, several mechanisms create immune barriers to further protect 
the body against luminal microbes including: epithelial tight junctions between cells prevent 
microbial movement between cells, a mucus layer produced by goblet cells prevents microbes 
from adhering to epithelial cells, secretory Immunoglobulin A (IgA) identifies pathogens within 
the intestinal lumen for removal, and an immune cell dense lamina propria directly beneath the 
intestinal epithelium layer27,156. 
In a healthy GIT, most microbial products that cross the epithelial barrier are contained and 
removed by macrophage phagocytosis within the lamina propria and mesenteric lymph nodes26,40. 
In pathogenic lentiviral infections, the integrity and structure of the GIT and GALT is 
compromised, enabling microbial translocation26,40. In non-human primates infected with 
pathogenic SIV, structural loss of tight junctions between intestinal epithelial cells, small foci of 
epithelial cell erosion, increased crypt enterocyte turnover and evidence of lymphocytic-
plasmacytic inflammatory infiltrates occur 14-28 days post-infection and continue into the 
chronic stage of disease157. In HIV and SIV-infected individuals, GALT undergoes severe CD4 T 
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cell depletion during the acute phase of infection that exceeds the level of CD4 T cell depletion 
seen in peripheral blood and lymph nodes25,158,159. Furthermore, restoration of CD4 T cell counts 
of GALT is delayed and incomplete even at 5 years post-infection25,158. The CD4 T cell 
population of GALT contains a larger proportion of CCR5+CD4+ T cells, the primary target for 
HIV and SIV, than other lymphoid tissues and peripheral blood and likely serves as a reservoir 
for infection and viral replication. The CD4 and CD8 T cells within GALT of HIV-infected 
patients, also express a higher proportion of activated phenotypes (CD25+, CD27-) at the expense 
of naïve or resting T cell phenotypes contributing to the risk for microbial translocation, 
compared to HIV-negative patients25,158,159. 
SIV-infection of non-human primates is pathogenic in certain species and not in others. In either 
case, infection causes marked deletion of T cells in intestinal mucosal and peripheral lymphoid 
tissues as well as lymphoid hyperplasia and lymphoid fibrosis160,161. However in species for 
which the virus is not pathogenic, infected animals do not have the same degree of intestinal 
barrier compromise or deleterious secondary infections as seen in animals for which the virus is 
pathogenic. In a study by Estes et al157, it was shown that during pathogenic SIV infection, Gram-
negative bacterial products, including lipopolysaccharide (LPS), were present in the lamina 
propria of GALT adjacent to the sites of epithelial barrier compromise. Gram-negative bacterial 
products were also identified in mesenteric lymph nodes draining the gastrointestinal tract (GIT), 
axillary lymph nodes and liver. LPS was identified in the medullary cords, sinuses, paracortex 
and germinal centers of affected lymph nodes. There was a positive correlation between the 
quantitative amount of LPS within the lamina propria and mesenteric lymph nodes and axillary 
lymph nodes. There were no bacterial products in the lamina propria of GALT, GI lymph nodes, 
peripheral lymph nodes or liver in the non-human primates for which the virus is not pathogenic. 
This supports the theory that alterations in lymphoid tissue T cell populations and structural 
compromise of the intestinal epithelial barrier in pathogenic infection permit primary bacterial 
translocation. Once disseminated, these bacteria and bacterial products are a source of chronic 
systemic immune activation. 
The innate immune system functions as the surveillance system to identify pathogens. The 
macrophages, neutrophils and dendritic cells utilize pathogen recognition receptors (PRR) on 
their outer membrane to identify highly conserved epitopes, termed pathogen associated 
molecular patterns (PAMP), located on pathogens. These receptors include toll-like receptors 
(TLR) that recognize certain bacteria, viruses and fungi, and glucan, mannose, and scavenger 
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receptors that recognize certain cell wall components of bacteria, yeast and fungi. The presence of 
PAMPs, found only on the outer membrane of pathogens, serve as a danger signal to alert the 
immune system to a foreign invader. Examples of PAMPs include lipopolysaccharide (LPS) of 
Gram-negative bacteria, lipotechoic acid (LTA) of Gram-positive bacteria and mannose-rich 
oligosaccharides of yeast and fungi. Once a PRR has bound to a PAMP it starts a cascade of 
events including pro-inflammatory cytokine production, extravasation of innate cells into tissues, 
chemotaxis of cells to the site of infection and antigen presentation to cells of the adaptive 
immune system84,105. 
Gram-negative bacteria are a primary component of the microbial population within the GIT. 
LPS, a PAMP on Gram-negative bacteria, is a potent immunostimulatory agent and is readily 
recognized by PRRs on marcophages of the innate immune system, in particular TLR-4 and 
CD14. The immune signaling pathway caused by the presence of LPS is complicated and not 
fully understood, however, it is known that multiple protein molecules play a role in the signaling 
cascade. Currently, it is known that the lipid A tail of LPS is the potent immunostimulatory 
region of the antigen. The lipid A portion is bound to the N-terminus of lipopolysaccharide 
binding protein (LBP), an acute phase serum protein that is produced by hepatocytes, epithelial 
cells and muscle cells. It is the C-terminus end of LBP that binds to CD14 to complete the 
trimerization of LPS-LBP-CD14. Once this trimer is formed, further signaling through the TLR-
4/MD-2 complex on the macrophage is carried out to produce pro-inflammatory cytokines such 
as interleukin-6 (IL-6), IL-1β, and tumor necrosis factor alpha (TNF-α)162. In low concentrations 
of LPS, LBP extracts LPS from the Gram-negative membrane and transfers it to CD14. In high 
concentrations of LPS, LBP will shuttle LPS to serum lipoproteins or form LPS aggregates for 
removal from the body through other mechanisms162-167. 
CD14, a key glycoprotein in the immune signaling cascade following LPS detection, is expressed 
by monocytes, macrophages and neutrophils and occurs in membrane bound (mCD14) and 
soluble forms (sCD14)162,163. Although sCD14 is most notably associated with LPS activation 
there is also evidence that it can enhance LTA, lipoarabinomannanes, peptidoglycans and other 
glycoprotein signaling168. Soluble CD14 is necessary for an immune signaling response in low 
concentrations of LPS. In addition to the trimerization pathway outlined above there is a second 
pathway that sCD14 is thought to employ to initiate an LPS signaling cascade. In this second 
pathway, sCD14 binds LPS in circulation and shuttles it to the MD-2 receptor of the macrophage 
after which sCD14 is released and recycled back into circulation. The LPS bound to MD-2 causes 
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a conformational change in the TLR-4 receptor on the surface of the macrophage which in turn 
carries out the LPS intracellular signaling cascade and pro-inflammatory cytokine production. It 
is thought that at high LPS concentrations sCD14 may act similar to LBP and shuttle LPS to 
lipoproteins for removal from the body163. 
Recently, LPS, sCD14 and LBP have been identified as plasma biomarkers of immune activation 
that can be used to monitor for progression of disease in HIV-infected patients26,40,169. Plasma 
concentrations of sCD14, LBP and LPS are increased in HIV and SIV infected individuals 
compared to uninfected individuals and are further increased in chronically infected individuals 
compared to acutely infected individuals26,169-172. Soluble CD14 in plasma has also been shown to 
be an independent predictor of mortality in HIV-infected patients and is positively correlated with 
T cell activation in early HIV infection173. 
Bacterial 16S rRNA products have been found in peripheral blood samples of chronically HIV-
infected patients with high plasma concentrations of sCD14, LPS and LBP, further indicating 
microbial translocation is an underlying cause of immune activation and disease 
progression 26,37,174-179. 
Measurement of circulating LPS and bacterial 16S rRNA are considered direct evidence of 
microbial translocation, but use of these tests can be challenging40,171. Samples can easily become 
contaminated with bacteria or LPS at collection or during handling. Detection of bacterial 16S 
rRNA is also dependent upon primer choice, PCR reaction conditions, and amount of microbial 
products in circulation. The assays for LPS are technically challenging to perform and results are 
often difficult to replicate. Soluble CD14 and LBP are considered surrogate markers for microbial 
translocation as they are produced secondary to immune stimulation by LPS, and are positively 
correlated with plasma and serum LPS concentration40,171. Plasma LBP and sCD14 are measured 
using enzyme-linked immunosorbent assays (ELISA). Results of these assays have been 
replicated within and between laboratories making them more robust markers of microbial 
translocation than LPS quantitation or 16S rRNA PCR assay40. 
Chronic immune activation as an underlying cause of disease progression in HIV-infected 
patients is now generally accepted. Microbial translocation as an underlying cause of chronic 
immune activation is now recognized as a significant factor in disease progression for HIV-
infected patients. Although the traditional monitoring techniques, CD4 T cell counts and viral 
load levels, are still the cornerstones of HIV patient care, the use of plasma biomarkers of chronic 
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immune activation as a monitoring tool is increasing and some researchers and clinicians suggest 
that it will become a routine part of HIV patient care. 
Given the similarities between FIV and HIV - depletion of T cells, alteration in cytokine profiles, 
and chronic immune activation - exploration and investigation into microbial translocation in 
FIV-infected cats is prudent. Research into a feline specific immunoassay to assess the level of 
circulating sCD14 in FIV-infected cats is ongoing and preliminary results show promise for use 
of this assay in detecting increased inflammation associated with FIV disease progression (Dr. 
Gregg Dean, personal communication). Discovery of an easy and readily available biomarker of 
immune health, in contrast to T cell levels and viral loads, would potentially allow for better 
characterization of immune health and disease stage, improved and focused medical interventions 
prior to development of clinical signs of disease, and enhanced length and quality of life. This 
would not only impact the lives of client-owned FIV-infected cats but also those infected cats 
residing within shelters. Improved ability to determine and monitor the immune health of FIV-
infected cats within shelters would provide beneficial information that could improve the 
adoptability, care and management of these cats. 
2.10 Future Treatment 
As microbial translocation has become an accepted pathway for chronic immune activation in 
HIV infection, the composition and relative abundance of bacterial species within the intestinal 
microbiome has become more relevant. With the invention of high-throughput sequencing, 
investigation into the intestinal microbiome has become increasingly easier and more common. 
Dysbiosis, fluctuations in bacterial population and composition, of the intestinal microbiome has 
become a focus of pathology in several diseases associated with a pro-inflammatory state 
including irritable bowel syndrome, diabetes mellitus and HIV. 
In recent years, several studies have examined the microbiome of HIV-infected patients 
compared to uninfected controls and revealed significant differences between the two groups180-
182. In general, researchers have reported an increase in Pseudomonas aeruginosa and Candida 
albicans and a decrease in Lactobacillus and Bacteroides spp. in fecal samples of HIV-infected 
individuals compared to uninfected controls180-182. Despite the difference in abundance of specific 
bacteria both groups had an equal richness in microbial diversity180,181. Differences in bacterial 
abundance based on sampling techniques such as mucosal biopsy, rectal swab or fecal sample are 
of concern. A recent study compared the microbiome of colonic mucosal samples to rectal swabs 
and fecal samples within individual patients, both HIV-infected and uninfected controls, and 
34 
 
reported that bacterial populations determined by sequencing techniques were not the same 
between sampled groups or sample types180. Colonic mucosal samples contained a higher 
abundance of Prevotella spp in the HIV-infected patients compared to uninfected controls. 
Prevotella spp were of much lower abundance in swabs and fecal samples in HIV-infected 
patients compared to colonic mucosal samples180. Prevotella spp are a Gram-negative pathobiont 
bacteria associated with other GI inflammatory diseases and are known for their ability to degrade 
mucin at the epithelial lining, disrupt epithelial tight junctions and contribute to intestinal barrier 
dysfunction180. Whereas the alterations in Bacteroides and Lactobacillus spp in rectal swabs and 
fecal samples were consistent between sampled group and sample type and also consistent with 
findings reported in similar studies181,182. 
In addition to bacterial composition and abundance, several studies have reported associations 
between certain bacterial species and elevations in markers of immune activation. Certain 
bacterial species, including Prevotella and Enterobacteria spp, have been associated with 
increased immune parameters including plasma viral load, colonic viral load, and plasma IL-6, 
IL-1β, LPS, and sCD14 concentrations180,181. But further studies must be done to establish a cause 
and effect relationship between dysbiosis and immune activation. 
The acceptance of microbial translocation as an underlying cause of immune activation has 
ushered in an additional approach to HIV therapy aimed at supporting immune health and 
integrity. These approaches aim to decrease HIV pathologic sequelae including: viral replication 
within the GI mucosa, microbial translocation, lymphoid fibrosis and immune activation183,184. 
The use of raltegravir burst therapy in combination with traditional HAART medications has 
been shown to decrease reservoir viral replication within the GI mucosa and support restoration 
of CD4 T cell populations and decrease local inflammation183. Several studies have reported 
beneficial effects of prebiotics and probiotics in supporting the abundance of “good bacteria” 
such as Lactobacillus spp within the GIT resulting in increased GI mucosal CD4 T cell 
populations, deceased GALT lymphoid fibrosis and decreased T cell turnover within GALT185,186. 
One study in HIV-infected children, diagnosed with failure to thrive despite HAART 
medications, reported an increase in height and weight gains after 5 months of probiotic therapy 
compared to a placebo group187. 
The use of LPS binding agents in SIV-infected patients, such as sevelamer, have been reported to 
block microbial translocation by clearing LPS from the GIT and stabilizing sCD14 and LPS 
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concentrations as compared to those patients not receiving the drug in which sCD14 and LPS 
levels continued to increase188. Further studies investigating the use of medications to influence 
bacterial colonization and inflammation within the gut of HIV-infected patients are ongoing and 
include: the antibiotic, rifaximin, which concentrates in the GIT; the anti-inflammatory, 
mesalamine, that concentrates activity in the GIT; and chloroquine that inhibits toll-like receptor 
immune activation183,184,189. Additionally, the angiotensin converting enzyme inhibitor, Lisinopril, 
is being studied for its potential role in reducing lymphoid fibrosis by reducing angiotensin II 
which is reported to be associated with fibrosis by increasing levels of TGF-β1183. 
To date, characterization of the intestinal microbiome in FIV-infected cats is limited and 
investigation into therapies aimed at modifying immune activation in FIV-infected cats are 
lacking. One study reported no difference in microbiome richness, diversity or evenness between 
FIV-infected cats and uninfected cats; but FIV-infected cats had a higher percentage of 
Bifidobacteriales, Lactobacillales and Aeromonadales at the order level190. Based on operational 
taxonomic units, there was diversity in community membership and structure in FIV-infected cats 
compared to uninfected cats190. The difference in bacteria type compared to bacterial function was 
not performed. Investigation into the use of probiotics in FIV-infected cats showed decreased 
bacterial translocation in an ex vivo evaluation of small intestinal mucosa, suggesting some 
probiotics may be effective supportive therapy191. Several studies investigating the use of 
recombinant feline interferon-omega have reported clinical improvement and decreased viral 
shedding of upper respiratory pathogens in FIV-infected cats but none have reported an 
improvement in immune status such as CD4 T cell counts and viral load192-194. 
2.11 Conclusion 
Feline immunodeficiency virus is an important, widespread, global disease in cats that causes 
progressive immune compromise which results in increased susceptibility to opportunistic 
infection, neoplasia and early death. Similar to human immunodeficiency virus (HIV) in people, 
FIV-infected cats have alterations in T cell counts, cytokine alterations, chronic immune 
activation and a decreased response to pathogens. Alterations in T cell populations, cytokine 
production and immune activation in the acute and asymptomatic stages of experimental FIV 
infection have been well documented and further understanding of the mechanisms associated 
with these changes is ongoing. However, despite these great strides in understanding this disease, 
the factors that propel a patient from asymptomatic to end stage disease are still unknown. 
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Unlike HIV-infected people, FIV-infected cats do not have access to advanced routine monitoring 
techniques, like CD4 T cell counts and viral loads, to identify progression of disease. This puts 
FIV infected cats and the veterinarians who care for them at a disadvantage. Investigation into 
inflammatory and lymphocyte immunophenotype health markers currently available is needed. 
Development of health panels that specifically monitor health parameters associated with 
inflammation such as white blood count, neutrophil count, albumin and globulin levels and CD4 
T cell and CD8 T cell counts should be pursued. Additionally, optimizing the frequency for 
which FIV-infected cats should be examined and monitored should also be performed. This 
would allow veterinarians to identify early alterations in inflammation and immune cell activity 
and intervene with medical therapies or preventative treatment earlier to extend good quality of 
life. 
Recent work in the study of HIV has found that chronic immune activation is associated with 
disease progression and early mortality. As such, new techniques to determine factors associated 
with immune activation have been developed for use in HIV-infected people. These techniques 
have the potential to advance patient monitoring, identify disease progression earlier, and guide 
future medical intervention to prolong health, thwart disease progression and increase quality of 
life. 
Given the similarities between FIV and HIV, it is plausible that these same techniques will be 
applicable to FIV-infected cats and will provide an easy diagnostic technique to identify disease 
progression. Continued investigation into the underlying mechanisms of disease progression will 
lead to novel therapies aimed at reducing immune activation and improved management protocols 
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CHAPTER 3. TEMPORAL PATTERNS IN GENERAL HEALTH PANEL MARKERS 
AND LYMPHOCYTE IMMUNOPHENOTYPE IN CATS NATURALLY INFECTED 





Feline immunodeficiency virus (FIV) is a complex, important lentiviral infection of cats. FIV 
infection causes immunosuppression and may lead to an increased risk of certain opportunistic 
infections, neoplasias and early mortality. The overall prevalence of FIV is reported to be 
approximately 2.5% in the United States 1,2. Transmission of FIV among cats occurs primarily via 
inoculation of virus via penetrating wounds. Male, intact, outdoor cats are at increased risk for 
acquiring FIV infection due to territorial fighting behavior3. Transplacental and transmammary 
transmission in experimental settings has been reported but this is not considered a common 
mode of transmission in naturally acquired infection.4,5 
FIV infections typically progress through three stages: acute, chronic (asymptomatic) and 
symptomatic (end stage). During the acute phase of infection cats may have anorexia, diarrhea, 
lethargy, fever and lymphadenomegaly beginning approximately 6 weeks post-infection6,7. The 
acute phase may last for several weeks and is followed by the asymptomatic phase during which 
cats show no outward signs of infection. The asymptomatic phase typically lasts for a variable 
period of years. During chronic infection, there are changes in the immune system of infected 
cats, and cats may be at risk for illnesses such as gingivostomatitis, upper respiratory infections 
and diarrhea, although these typically respond to treatment. Some cats progress to a final 
symptomatic stage of infection which is marked by an ongoing loss of body condition, treatment-
refractory opportunistic infections, blood dyscrasias, neoplasia and death.3,8 
During the acute phase of infection, cats may be anemic, leukopenic, lymphopenic and / or 
neutropenic but these abnormalities are transient. Cats in the chronic phase of infection may have 
relative leukopenia, lymphopenia and / or monocytopenia compared to FIV-uninfected cats but 
53 
 
values for asymptomatic FIV-infected cats typically remain within the reference 
interval9,10Additionally, hypergammaglobulinemia believed secondary to polyclonal B cell 
proliferation and increased immunoglobulin production has been reported in FIV-infected cats 
compared to FIV-uninfected cats9,11,12. Hypernatremia was reported in some FIV-infected cats 
although the cause for this was unknown11. For those cats progressing to end stage disease, 
marked anemia, leukopenia, neutropenia and lymphopenia are most commonly reported although 
reports of blood dyscrasias in symptomatic infection are sparse13,14. 
It is well documented in experimental infection that CD4 T cell percentages and absolute cell 
counts may markedly decrease during the acute phase of infection, rebound during the early 
asymptomatic phase (typically not to pre-infection levels) and then gradually decline over the 
remainder of infection10,15-18. The CD8 T cell population has been shown to increase following 
infection and this is reportedly due to an expansion of the CD8 T cell subset, CD8βlow 17,19. 
CD8βlow cells are thought to be activated effector cells as based on phenotype and have been 
shown to decrease FIV replication in vitro; these cells may increase as early as 3 weeks post 
infection and are reported to comprise up to 70% of the total CD8 T cell population19,20. In one 
experimental infection, CD4 T cell counts of  FIV-infected cats 18 months post-infection were 
691±130 cells/mm3 compared to 1450±46 cells/mm3 in FIV-uninfected cats17. In this same 
population of FIV-infected cats, CD8βlow cells were reported as 352±59 cells/mm3 at 18 months 
post-infection compared to 158±61 cells/mm3 in FIV-uninfected cats17. The decrease in CD4 T 
cells and increase in CD8/CD8βlow cells, results in an inversion of the CD4:CD8 ratio in FIV-
infected that persists throughout infection9,10,18,21. In one study of experimentally infected cats, the 
CD4:CD8 ratio inversion was reported to be statistically significant as early as 6 weeks post-
infection and at each time point thereafter compared to uninfected control cats. The averaged 
CD4:CD8 ratio was reported as 0.75±0.47 in chronically FIV-infected cats compared to 
1.65±0.38 in FIV-uninfected cats10. 
The majority of information detailing progressive hematological, biochemical and lymphocyte 
immunophenotype abnormalities of FIV-infected cats has been gained through studies of 
experimental infection. While experimental infections are very important to allow controlled 
study of the course of FIV infections, it is not known whether experimental infection accurately 
mimics natural infection. Experimentally infected cats are often inoculated as kittens, whereas it 
is believed that the majority of naturally infected cats are infected with FIV as adult cats. 
Experimentally infected cats are housed in specific pathogen free (SPF) conditions, and often 
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inoculated via intraperitoneal, intravenous or mucosal routes rather than deep, penetrating bite 
wounds. SPF housing conditions limit environmental pathogen exposure and protect cats from 
exposure to common pathogens encountered by naturally infected cats. It is not known whether 
experimental FIV inoculation doses and strains are similar to those encountered in natural 
infection. It is therefore difficult to make generalizations or predictions about disease progression 
in naturally acquired infection based on results from experimental infection. 
The purpose of this study was to compare the temporal patterns of common hematological, 
plasma biochemical and lymphocyte immunophenotype values between FIV-infected cats and 
FIV-uninfected cats and also between FIV-infected cats residing in private homes and infected 
cats residing in sanctuary housing over a period of up to 4 years . The study was designed to test 
the following hypotheses: in comparison to FIV-uninfected cats, FIV-infected cats will have 
different temporal patterns in: 1) CD4 and CD8 lymphocyte numbers and ratios; 2) hematological 
parameters and 3) plasma biochemical parameters. Furthermore, there will be different temporal 
patterns in these parameters in FIV-infected cats residing in sanctuary housing compared to FIV-
infected cats residing in private homes of <7 cats. 
3.2 Materials and Methods 
3.2.1 Animals   
Cats were enrolled from adoption guarantee shelters (PAWS Chicago and Treehouse Humane 
Society, (Chicago, IL)), the Fitzhugh B. Crews FIV Sanctuary (Memphis, TN), or private homes 
in the Chicago, IL and Memphis, TN metropolitan areas.  Cats were considered FIV-infected 
when enzyme linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) were 
both positive at the time of enrollment. Any cat with discordant results had virus isolation (VI) 
performed and this result determined the FIV status of the cat. Date of initial FIV infection was 
not known for any of the cats at the time of enrollment; therefore chronicity of infection for the 
cats in this study was unknown. Any cat testing positive for feline leukemia virus (FeLV) at 
enrollment was excluded from the study. 
3.2.2 Laboratory findings   
Cats were examined every 12 months. At enrollment and at each subsequent examination time 
point, blood was collected and submitted to IDEXX Laboratories (Westbrook, ME) for complete 
blood count (CBC), plasma biochemistry, and FIV/FeLV ELISA test (SNAP® FIV/FeLV test, 
IDEXX Laboratories, Westbrook, ME). Lymphocyte immunophenotyping was performed at 
IDEXX Laboratories (Westbrook, ME) or Purdue University (West Lafayette, IN). Lymphocyte 
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immunophenotyping was performed using the protocol described by Lin et al22. PCR for FIV 
(FIV Real PCR™ Test) was performed at IDEXX Laboratories (West Sacramento, CA) using 
proprietary primers and methodology. Virus isolation was performed at the University of 
Glasgow Centre for Virus Research (Glasgow, United Kingdom)23. The following laboratory 
parameters were evaluated in FIV-infected and FIV-uninfected cats: hematocrit (HCT), leukocyte 
count (WBC), neutrophil count (NEUT), lymphocyte count (LYMPH), blood urea nitrogen 
(BUN), creatinine (CREA), total protein (TP), albumin (ALB), globulin (GLOB), alkaline 
phosphatase (AlkP), and alanine aminotransferase (ALT) activities, cholesterol (CHOL), glucose 
(GLUC), sodium (NA), urine specific gravity (USG), CD4 count, total CD8 count, 
CD8βlow count, and CD4:CD8 ratio. Reference intervals for hematological and plasma 
biochemical markers and lymphocyte immunophenotype are listed in Table 1. 
3.2.3 Statistical analysis  
Data were analyzed using commercially available statistical software (IBM SPSS for Windows 
version 22). Descriptive statistics are reported and laboratory parameter values are reported as 
median and range. General linear mixed models regression (GLMM) was used to assess temporal 
patterns in laboratory parameters, comparing these values between FIV-infected and FIV-
uninfected cats and also between FIV-infected cats living in sanctuary housing and FIV-infected 
cats living in private homes with <7 cats. GLMM was used to account for repeated measures over 
time within individual cats. Intraclass correlation coefficient (ICC) was calculated for each 
laboratory parameter to determine the variation within each cat that contributed to the total 
variations. Age at enrollment was adjusted in all models. The GLMM analyses were performed 
separately by three time intervals from enrollment to year 2, year 3, and year 4 in order to 
investigate potential effects of non-random withdrawal (i.e. due to death) of study cats over time. 
Within each time interval, only cats that had data at all time points were included in the analysis. 
Normality for each variable was assessed using the Shapiro-Wilk statistic (>0.85). Mathematical 
data transformations (e.g. log) were applied to correct parameters with a skewed distribution. 
Statistical significance is set at P <0.05. 
3.3 Results 
A total of 174 cats were evaluated at enrollment, with 87 FIV-infected cats (29 female spayed 
(FS) and 58 male neutered (MN)) and 87 FIV-uninfected cats (30 FS and 57 MN) and the median 
age of 5 years (range: 1.5 – 11). There were 104 cats available for temporal pattern comparison 
over the 3 year duration including 43 FIV-infected and 61 FIV-uninfected with a median age of 4 
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years (range: 1.5 – 10). The number of cats evaluated at each interval decreased due to death or 
dropout of cats for other reasons (e.g. owners moved away or no longer were able to participate). 
The sample size of cats included for each interval is summarized in Table 2. However, no obvious 
differences were found in the temporal patterns among the three time intervals. Therefore, only 
the results of the interval from enrollment to year 2 for overall differences between groups and 
enrollment to year 3 for temporal change were reported. 
The data for the following laboratory parameters were right skewed and log transformed for all 
statistical analyses: CD4, CD8, CD8βlow, CD4:CD8 ratio, WBC, LYMPH, NEUT, BUN, CREA, 
ALT, ALKP, CHOL, GLU, and TP. 
3.3.1 Overall differences in laboratory parameters between FIV-infected and uninfected 
cats 
FIV-infected cats had consistently higher values for CD8βlow cells, TP and GLOB compared to 
FIV-uninfected cats (P <0.001 for each; Figures 1, 2 and 3). The CD4:CD8 ratio was consistently 
lower in FIV-infected cats compared to FIV-uninfected cats (P <0.001; Figure 4). 
3.3.2 Temporal changes in laboratory parameters of FIV-infected cats vs. FIV-uninfected 
cats 
There were statistically significant differences in temporal patterns between FIV-infected and 
FIV-uninfected cats for CD4, CD8 and LYMPH. CD4 and CD8 values decreased in both FIV- 
infected and FIV-uninfected cats overtime, but the loss of cells was greater in FIV-infected cats 
(Figures 5 and 6). LYMPH values decreased in FIV-infected cats but remained stable over time in 
FIV-uninfected cats (Figure 7).  
For FIV-infected cats, compared to FIV-uninfected cats, statistically significant differences in 
temporal patterns were found for HCT, ALB, and BUN although the overall change was small. 
Median and range laboratory parameters and P-values are summarized in Table 3. The FIV-
infected cats showed a decreasing temporal pattern in HCT values while an increasing pattern 
was observed in FIV-uninfected cats. Temporal patterns for ALB showed a decreasing pattern for 
FIV-infected cats whereas values remained stable in FIV-uninfected cats. BUN values were lower 
in FIV-infected cats and showed a deceasing pattern compared to stable values in the FIV-
uninfected cats. 
There were no statistically significant differences between FIV infected and uninfected cats for 
the following laboratory parameters: WBC, ALT, ALKP, GLU, NA and USG. 
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Intraclass correlation coefficient percentages for laboratory parameters with statistically 
significant temporal changes ranged from 43 – 96%. BUN had the lowest ICC percentage and 
CHOL had the highest ICC percentage (data not shown). 
3.3.3 Overall differences in laboratory parameters between FIV-infected cats in sanctuary 
housing and FIV-infected cats 
FIV-infected cats had consistently higher laboratory parameter values for GLOB (P = 0.002) and 
NEUT (P = 0.019) compared to FIV-infected cats living in private homes (Figures 8 and 9). 
Laboratory parameter values were consistently lower for ALB (P <0.001) and CHOL (P = 0.001) 
in sanctuary housed cats compared to cats in private homes (Figures 10 and 11). 
3.3.4 Temporal changes for laboratory parameters of FIV-infected cats in private homes vs. 
FIV-infected cats in sanctuary housing  
There were statistically significant differences in temporal patterns for the following laboratory 
parameters: CREA, HCT, WBC, TP, BUN and ALT in FIV-infected cats in sanctuary housing 
compared to FIV-infected cats in private homes, although the overall change was small. 
Laboratory parameter values and P-values are summarized in Table 3. 
CREA values for FIV-infected cats living in sanctuary housing were lower and decreased over 
time compared to FIV-infected cats in private homes for which values remained stable. For HCT, 
a decreasing temporal pattern and lower values were observed for FIV-infected sanctuary housed 
cats compared to an increasing pattern for FIV-infected cats in private homes. For FIV-infected 
cats in sanctuary housing, the BUN pattern decreased over time and values were lower compared 
to FIV-infected cats in private homes for which values remained stable. Laboratory parameter 
values for ALT showed an increasing pattern for FIV-infected cats in sanctuary housing 
compared to a decreasing pattern in ALT for FIV-infected cats in private homes. 
A difference in temporal pattern for WBC in FIV-infected cats in sanctuary housing compared to 
FIV-infected cats living in private homes was seen. Median WBC counts and maximum range 
values were consistently higher in sanctuary housed cats compared to stable values for cats in 
private homes. TP values showed an increasing pattern for FIV-infected cats in sanctuary housing 
compared to a decreasing pattern for cats in private homes, although values were higher in 
sanctuary housed cats. 
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There were no statistically significant differences in temporal change between the 2 FIV-infected 
groups for CD4, CD8, and CD8βlow counts, CD4:CD8 ratio, LYMPH, ALKP, GLU, NA or USG 
values (data not shown). 
The ICC percentages for markers with statistically significant temporal change comparisons 
ranged from 42 - 58%. HCT had the lowest ICC percentage and WBC had the highest ICC 
percentage (data not shown). 
3.4 Discussion 
The results of this study show that cats naturally infected with FIV had differences in multiple 
laboratory parameters, and among these, some parameters had differences in temporal patterns 
compared to FIV-uninfected cats. FIV-infected cats had consistently higher values for 
CD8βlow cells, globulin levels and total protein levels and lower CD4:CD8 ratio values compared 
to FIV-uninfected cats. Differences in temporal patterns were seen forCD4 and total CD8 T cell 
values, absolute lymphocyte counts, hematocrit, blood urea nitrogen (BUN), cholesterol and 
albumin in FIV-infected cats compared to FIV-uninfected cats. For FIV-infected cats living in 
sanctuary housing consistently higher values for globulin levels and absolute neutrophil counts 
and lower values for albumin and cholesterol levels. Differences in temporal patterns were seen 
for hematocrit, albumin, BUN, creatinine, absolute white blood cell counts and total protein in 
FIV-infected cats living sanctuary housing compared to cats in private homes, however, changes 
were small. The biological importance of small changes in temporal patterns within or just above 
the reference interval is not known and may be indicative of disease within an individual cat 
rather than a trend within the group. Furthermore, based on ICC values, there is a high degree of 
variability within the individual cats of each group, although slightly less variability within the 
FIV-infected cats. 
The temporal pattern in CD4 T cells in FIV-infected cats compared to FIV-uninfected cats was 
expected. The lower number of CD4 T cells in FIV-infected cats compared to FIV-uninfected 
cats has been documented in the literature in both experimental and naturally acquired 
infection9,10,16,17. CD4 T cells are the primary target of the virus and loss of these cells occurs in 
peripheral blood as well as lymphoid tissue, particularly in the gut-associated lymphoid tissue 
(GALT) 15,24,25. It was somewhat surprising that CD4 T cell counts of FIV-uninfected cats 
decreased over time, similar to the FIV-infected cats. Median CD4 T cell counts fell below the 
low end of the reference interval by year 3 of the study but values for uninfected cats remained 
within the reference interval (543 – 1820 cells/µL) reported for healthy adult cats26. Temporal 
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patterns for CD8 T cell counts showed a decreasing pattern in both FIV-infected and FIV-
uninfected cats, although the pattern was more pronounced in FIV-infected cats but neither group 
had a median value below the reference interval. FIV-infected cats had higher CD8 T cell counts 
compared to FIV-uninfected cats, which was not entirely unexpected. The higher CD8 T cell 
values in FIV-infected cats were hypothesized to be the result of expansion of CD8βlow cells in 
FIV-infected cats, which occurs soon after infection and is reported to continue throughout the 
chronic stage of disease17. In this population of cats, the CD8βlow cells were consistently higher in 
FIV-infected cats compared to FIV-uninfected cats but failed to show continued expansion over 
time. As the duration of FIV infection was unknown for the cats in this study, it may be that these 
cats had reached a plateau in CD8βlow production, and that is why there was not a significant 
difference in temporal change for this parameter. Furthermore, it has been postulated that 
CD8βlow cells may transform to CD8β-negative (CD8βneg) cells in the late stages of chronic 
infection19 but CD8βlow cell counts have not been widely documented in experimental infection so  
it is not known how this population changes over time. Lymphocyte immunophenotyping for 
CD8βneg cells was not performed in this study and therefore any change in this population was not 
seen. 
In two longitudinal studies of experimentally infected cats and uninfected controls, it was shown 
that absolute CD4 T cell counts fluctuate over time in both FIV-infected and FIV-uninfected cats 
and at times showed a decreasing trend in the FIV-uninfected cats10,18. The intracorrelation 
coefficient CD4 and CD8 T cell percentages for the cats in this study support large variation for 
these values within cats. It has been reported that in healthy cats there is a loss of absolute CD4 
and total CD8 T cells in peripheral blood of senior cats (10-14 years old) compared to adult cats 
(2-5 years old) that is similar to what is seen in aging people and mice27. Additionally, a loss of 
absolute B cells in peripheral blood of senior cats was also reported but interestingly 
immunoglobulin levels were found to be increased in the senior cats27. Immunosenescence, the 
result of multiple changes to the immune system over time, is associated with loss of leukocytes, 
lymphocytes and increases in inflammatory cytokines which affect immune response and increase 
susceptibility to infection and disease in geriatric mammals, although this has not been widely 
studied in cats28. Immunosenescence may have played a role in the loss of T cells and lymphocyte 
numbers and globulin levels higher than the reference interval in FIV-uninfected cats. 
In a recent longitudinal study of experimental FIV infection, FIV infected cats had higher CD8 T 
cell counts compared to uninfected control cats10. Gradual declines in CD8 T cell counts were 
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noted in half of those FIV-infected cats, whereas the remaining FIV-infected cats appeared to 
have stable counts. CD8 T cell counts of uninfected control cats appeared stable over time10. 
However, the authors reported no statistical difference in absolute CD8 T cell counts between 
FIV-infected and uninfected cats, although a higher percentage of lymphocytes expressed the 
CD8 marker in FIV-infected cats compared to FIV-uninfected cats10. The CD8βlow cell population 
was not reported for that study10. CD8βlow cell populations have been reported to comprise up to 
70% of CD8 T cells ≥7 years post-FIV infection19,29 As experimentally infected cats are kept in 
SPF housing, it is not known how other viral pathogens may impact CD4 and CD8 T cell 
findings. Consistent with the decrease in CD4 and total CD8 T cell counts, lymphocyte numbers 
decreased over time in both FIV-infected and FIV-uninfected cats, although the decrease was 
greater in FIV-infected cats. As CD4 and CD8 T cells are a large portion of the lymphocyte 
population this finding is not unexpected. 
The temporal change and decreasing hematocrit in FIV-infected cats compared to FIV-uninfected 
and FIV-infected cats living in sanctuary housing compared to those in private homes, although 
mild, may reflect an early change in red blood cell counts associated chronic inflammatory 
disease. However, in each group the values remained within the reference interval making further 
biological interpretation of the results difficult. The differences in temporal pattern for albumin 
between FIV-infected cats and FIV-uninfected cats, and the lower albumin levels in sanctuary 
housed cats compared to cats in private homes, may be a result of inflammation associated with 
chronic disease in FIV infection. Chronic inflammation is associated with a decrease in negative 
acute phase proteins, such as albumin, and an increase in positive acute phase proteins. The 
production of pro-inflammatory cytokines can interfere with albumin production. It has been 
shown that FIV-infected cats have increased levels of pro-inflammatory cytokines in circulation. 
Loss of albumin can also occur through the kidneys, gastrointestinal tract and skin. However, 
other laboratory parameters and physical examination findings did not support those as likely 
reasons for decreasing albumin. 
The difference in temporal pattern for white blood cell counts between FIV-infected cats in 
sanctuary housing and cats in private homes and the higher median and maximal range WBC 
values for sanctuary housed cats  raises the question of whether environmental conditions play a 
role in FIV disease progression. It has been reported that cats living within sanctuary housing 
have a higher prevalence of upper respiratory infections with pathogens such as feline 
herpesvirus-1 (FHV-1), feline calicivirus (FCV), Bordetella bronchiseptica, Chlamydophila felis 
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and Mycoplasma disease compared to those in private homes. Although identifying 
environmental pathogen exposure was beyond the scope of this study, it is possible that the cats 
living in sanctuary housing were exposed to an increased number of pathogens, and therefore 
suffered a higher occurrence of concurrent viral and possible secondary bacterial infection which 
may have led to increased WBC. 
Plasma total protein levels were higher in cats living in sanctuary housing than in cats living in 
private homes and showed a difference in temporal patterns. The FIV-infected cats in sanctuary 
housing had consistently higher median and range globulin levels compared to FIV-infected cats 
in private homes, although a difference in temporal pattern was not found. Increased globulin 
levels in FIV-infected cats have been previously reported and are thought to be secondary to B 
cell stimulation and increased immunoglobulin production. Median values for albumin were 
lower in the sanctuary housed cats compared to those in private homes although no temporal 
change was found. The higher globulin levels and lower albumin levels could be a consequence 
of increased pro-inflammatory cytokines that favor humoral immunity and interrupt albumin 
production, but confirmation of increased cytokine levels was not performed. As duration of 
infection is unknown in these cats, an increasing trend in the change of globulin levels may have 
been masked due to the likely varied durations of infection. Additionally, a potential difference in 
pathogen exposure between sanctuary housed cats and cats in private homes causing a pro-
inflammatory response should be considered. This is further supported by increased WBC and 
absolute neutrophil counts in sanctuary housed cats compared to cats in private homes. 
Differences in temporal patterns for blood urea nitrogen (BUN) and creatinine were found in 
FIV-infected cats compared to FIV-uninfected cats and in FIV-infected cats in sanctuary housing 
compared to those in private homes. Additionally, a difference in temporal pattern for cholesterol 
in FIV-infected cats compared to uninfected cats and alanine aminotransferase (ALT) in FIV-
infected cats in sanctuary housing compared to FIV-infected cats in private homes. The changes 
in BUN, creatinine, cholesterol and ALT were small and the median values of each remained 
within reference intervals therefore the biological significance of these changes is not known; 
changes may be the result of concurrent disease within a specific cat rather than a trend within the 
group. A recent study showed no significant difference in renal values between FIV-infected and 
uninfected cats but found an increased urine protein-to-creatinine (UPC) ratio in FIV-infected 
cats30. The UPC ratio was not measured for cats in this study. Diagnostics to assess liver function 
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or intestinal mucosal integrity were not performed and further inference as to cause of differences 
in ALT and cholesterol cannot be made. 
There were several limitations to this study. Enrollment of cats in the study was ongoing for two 
years, therefore not all cats were monitored for a period of 4 years; some were only monitored for 
2 years. Although cats in both the infected and uninfected groups were lost to follow-up, more 
FIV-uninfected cats were lost to follow-up. This led to a greater attrition rate than expected over 
the course of the study and the resulting sample size may not have been large enough to detect 
significant differences in temporal patterns. Moreover, loss of cats over the duration of the study 
may have unintentionally favored selection of healthy cats that survived to the end of the study. 
In addition, the duration of the study may not have been long enough to observe the full impact of 
change over time in erythrocyte, leukocyte or lymphocyte subset populations or in albumin and 
globulin levels. The lack of an FIV-uninfected sanctuary housed population limited a more 
thorough investigation into the impact of environment on laboratory parameters. Virus isolation 
was not performed on all cats enrolled in the study and without the results of this test, considered 
the reference standard, there is a possibility that infection status was not correct in all cats. 
Finally, as the cats in this study were all naturally infected, and acquired from shelters with 
limited knowledge of any previous health history, there was no known duration of infection for 
direct comparison between the cats. Similarly, the age of the cats was an estimate made at the 
time of entry into the shelter and may not have been accurate, although adjustment for age was 
performed in the statistical analysis. 
3.5 Conclusion 
The results of this study showed that FIV-infected cats have higher values for absolute CD8βlow 
cell counts, total protein and globulin levels and lower CD4:CD8 ratio compared to uninfected 
cats. Additionally, differences in temporal patterns were seen for CD4 and total CD8 T cell 
values, absolute lymphocyte cell counts, hematocrit, BUN, creatinine and albumin levels 
compared to FIV-uninfected cats. Furthermore, FIV-infected cats in sanctuary housing had higher 
values for globulin levels and absolute neutrophil counts compared to FIV-infected cats living in 
private homes. FIV-infected cats in sanctuary housing showed differences in temporal patterns 
for WBC count, total protein, hematocrit, BUN, creatinine and alanine aminotransferase activity 
levels compared to cats that lived in private homes. Differences in laboratory parameter values 
and temporal patterns associated with inflammation and immune activity were seen in FIV-
infected cats compared to uninfected cats and FIV-infected cats in sanctuary housing compared to 
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cats that lived in private homes. These findings are consistent with those reported for 
experimental infection but raised the question of environmental impact on inflammation and 
immune response in the progression of disease in FIV infection. Particularly when inflammation 
and immune activation are two prominent aspects of FIV infection associated with disease 
progression and may be influenced by increased exposure to pathogens within the environment. 
Due to the small number of cats in this study and lack of an FIV-uninfected sanctuary housed 
control group, the results of this study are considered exploratory and cannot be extrapolated to 
the larger FIV-infected population. Further investigation into the potential impact of living 
environment on chronic FIV infection is warranted and should be pursued. At this time, CD4 and 
total CD8 T cell counts may be the most sensitive parameters by which to measure disease 
progression over the long duration of chronic infection. However, further efforts to define disease 
progression in FIV infection should include discovery of new biological markers that more 
accurately reflect the chronic inflammation and immune activation associated with FIV infection, 
rather than continued investigation into routine laboratory health parameters which may not be 




Table 3.1. Reference intervals for hematological, biochemical and lymphocyte 
immunophenotype markers 
a Reference intervals as used by Purdue University College of Veterinary Medicine 
b Dean GA et al. Veterinary Immunology and Immunopathology, 28 (1991) 327-335  
c Willett BJ et al Immunology, 78 (1993) 1-6 
Marker Reference interval Marker Reference Interval 
HCTa 30.0 - 45.0% BUNa 15 - 35 mg/dL 
WBCa 6.0 - 18.0 x10³/uL CREAa 0.9 - 2.3 mg/dL 
NEUTa 3.0 - 12.0 x10³/uL TPa 5.5 - 7.1 g/dL 
LYMPHa 1.50 - 7.0 x10³/uL ALBa 2.7 - 3.9 g/dL 
CD4b 543 - 1820 x10³/uL GLOBa 2.3 - 3.8 g/dL 
CD8b 353 - 994 x10³/uL ALKPa 23 - 107 U/L 
CD8βlow, c 97 – 219 x10³/uL ALTa 20 - 108 U/L 
CD4:CD8 ratio 1.2 – 2.6 CHOLa 45 - 274 mg/dL 
  GLUa 75 - 134 mg/dL 




Table 3.2. Sample size for groups at each time interval 
Groups (n) Followed 2 years Followed 3 years Followed 4 years 
FIV - 72 63 34 
FIV+ 51 43 26 
FIV+  
private home 32 28 13 
FIV+  







Table 3.3. Descriptive statistics (median and range) and P-values for selected laboratory 




Group Enrollment Year 1 Year 2 Year 3 P-value 
HCT 
FIV- 43 (34 – 62) 
45 
(33 – 62) 
45 
(28 – 55) 
78 
(18 – 63) 0.016 
FIV+ 42 (21 – 50) 
44 
(32 – 52) 
44 
(33 – 52) 
44 
(27 – 55) 
BUN 
FIV- 23 (14 – 38) 
24 
(17 – 32) 
23 
(15 – 52) 
24 
(15 – 41) 0.001 
FIV+ 22 (12 – 34) 
20 
(13 – 28) 
22 
(14 – 30) 
22 
(13 – 32) 
CHOL 
FIV- 154 (81 – 304) 
161 
(93 – 334) 
151 
(82 – 346) 
154 
(104 – 332) 0.03 
FIV+ 140 (76 – 316) 
139 
(81 – 303) 
136 
(73 – 336) 
128 
(70 – 334) 
ALB 
FIV- 3.5 (2.5 – 4.2) 
3.5 
(2.8 – 4.0) 
3.5 
(2.5 – 4.5) 
3.6 
(2.6 – 4.2) 0.015 
FIV+ 3.2 (2.5 – 3.9) 
3.4 
(2.5 – 3.9) 
3.3 
(2.7 – 3.9) 
3.1 





Table 3.4.  Descriptive statistics (median and range) and P-values for selected laboratory 










(32 – 50) 
45 
(34 – 52) 
46 
(33 – 52) 
46 
(31 – 55) 0.05 FIV+ 
sanctuary 
42 
(21 – 48) 
41 
(32 – 49) 
41 
(36 – 50) 
40 





(5.2 – 20.9) 
11.2 
(4.1 – 18.7) 
8.3 
(3.2 – 12.7) 
8.7 
(4.3 – 13.2) <0.001 FIV+ 
sanctuary 
12.7 
(4.5 – 23.7) 
11.1 
(6.6 – 24.6) 
10.1 
(6.0 – 26.7) 
12.3 





(6.5 – 9.9) 
8.1 
(6.8 – 9.6) 
8.0 
(6.7 – 9.2) 
7.7 
(6.4 – 9.2) 0.004 FIV+ 
sanctuary 
8.0 
(7.2 – 8.8) 
8.1 
(6.8 – 8.8) 
8.2 
(6.8 – 11.0) 
8.2 





(14 – 34) 
22 
(14 – 28) 
24 
(15 – 30) 
23 
(13 – 32) 0.03 FIV+ 
sanctuary 
20 
(12 – 28) 
18 
(13 – 22) 
18 
(14 – 23) 
20 





(0.9 – 2.0) 
1.5 
(1.0 – 1.9) 
1.5 
(1.0 – 1.9) 
1.5 
(1.1 – 2.2) <0.001 FIV+ 
sanctuary 
1.4 
(1.0 – 2.1) 
1.2 
(0.6 – 1.8) 
1.3 
(0.9 – 1.8) 
0.9 





(10 – 587) 
52 
(15 – 239) 
50 
(27 – 197) 
52 
(29 – 92) 0.007 FIV+ 
sanctuary 
50 
(26 – 82) 
47 
(14 – 115) 
46 
(12 – 96) 
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Figure 3.1. Descriptive statistics (median and range) for differences in absolute CD8βlow   T 
cell counts for FIV-infected and FIV-uninfected cats over 2 years 
Blue boxes: FIV-uninfected cats; Green boxes: FIV-infected cats, Open circles: extreme values; 





Figure 3.2. Descriptive statistics (median and range) for differences in total protein for FIV-
infected and uninfected cats over 2 year 
Blue boxes: FIV-uninfected cats; Green boxes: FIV-infected cats, Open circles: extreme values; 





Figure 3.3. Descriptive statistics (median and range) for differences in globulin levels for 
FIV-infected and uninfected cats over 2 years 
Blue boxes: FIV-uninfected cats; Green boxes: FIV-infected cats, Open circles: extreme values; 





Figure 3.4. Descriptive statistics (median and range) for differences in CD4:CD8 ratio for 
FIV-infected and uninfected cats over 2 years 
Blue boxes: FIV-uninfected cats; Green boxes: FIV-infected cats, Open circles: extreme values; 






Figure 3.5. Temporal patterns for absolute CD4 T cell counts in FIV-infected and 
uninfected cats over 3 years 





Figure 3.6. Temporal patterns for absolute CD8 T cell counts in FIV-infected and 
uninfected cats over 3 years 





Figure 3.7. Temporal patterns for absolute lymphocyte counts in FIV-infected and 
uninfected cats over 3 years 





Figure 3.8. Descriptive statistics (median and range) for differences in globulin levels for 
FIV-infected cats in sanctuary housing and FIV-infected cats in private homes over 2 years 
Blue boxes: FIV-infected cats in private homes; Green boxes: FIV-infected cats in sanctuary 





Figure 3.9. Descriptive statistics (median and range) for differences in absolute neutrophil 
counts for FIV-infected cats in sanctuary housing and FIV-infected cats in private homes 
over 2 years 
Blue boxes: FIV-infected cats in private homes; Green boxes: FIV-infected cats in sanctuary 





Figure 3.10. Descriptive statistics (median and range) for differences in albumin levels for 
FIV-infected cats in sanctuary housing and FIV-infected cats in private homes over 2 years 
Blue boxes: FIV-infected cats in private homes; Green boxes: FIV-infected cats in sanctuary 





Figure 3.11. Descriptive statistics (median and range) for differences in cholesterol levels for 
FIV-infected cats in sanctuary housing and FIV-infected cats in private homes over 2 years 
Blue boxes: FIV-infected cats in private homes; Green boxes: FIV-infected cats in sanctuary 
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CHAPTER 4. ILLNESS AND MORTALITY RATES IN CATS NATURALLY INFECTED 






Feline immunodeficiency virus (FIV) is an important life-long lentiviral infection in cats which 
leads to immunosuppression and increased risk of certain opportunistic infections, neoplasias and 
early mortality. Prevalence of FIV is estimated to be approximately 2.5% of owned cats in the 
United States however, prevalence is increased in cats  allowed outdoors (4.3%), those living in 
large shelters where environments are consistent with hoarding situations (8.8%), and in cats 
presenting to a veterinarian with clinical signs of illness (up to 20.6%) 1,2. Male, intact, outdoor 
cats are at greatest risk of infection due to territorial fighting behavior1,3,4. 
In FIV infection, disease course is typically categorized into three stages: 1) acute infection, 2) 
asymptomatic or chronic infection and 3) symptomatic or end stage infection. Acute infection 
may be characterized by transient signs of illness including lethargy, fever, lymphadenopathy and 
diarrhea that occur several weeks post-infection5. During this period there is a decrease in CD4 T 
cell counts, an increase in CD8 T cell counts due to expansion of the CD8βlow subset, and an 
inversion of the CD4:CD8 ratio5-8. The expansion of CD8βlow cells, unique to FIV-infected cats, 
are reported to have anti-FIV properties that aid is controlling viremia but an exact mechanism of 
action is unknown6,7,9. As cats transition into the chronic phase of infection CD4 T cells are 
restored but not to pre-infection levels. Chronic infection lasts for a variable period of years 
during which  patients show no outward signs of clinical illness on physical examination10. There 
is a slow decline in CD4 T cell counts, a continued expansion of CD8βlow cells, and continued 
decrease in the CD4:CD8 ratio6,8,11. Hypergammaglobulinemia is often reported in the chronic 
stage of FIV infection and is reported to be a polyclonal gammopathy secondary to FIV-related B 
cell stimulation. In a recent study it was reported that as cats progress to the symptomatic stage of 
infection plasma globulin levels are further increased compared to the asymptomatic stage of 
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infection12. Cats progressing to end stage immunodeficiency syndrome typically suffer loss of 
body condition, muscle wasting, treatment-refractory opportunistic infections, anemia, 
leukopenia, lymphopenia, neoplasia and death13.  It is anticipated cats will have a marked decline 
in CD4 T cells and CD4:CD8 ratio, anemia and leukopenia however, clinical pathological and 
lymphocyte immunophenotype data in end stage disease has not been well reported. The 
knowledge of biochemical and lymphocyte immunophenotype changes in cats with end stage 
disease is still sparse as there have been few studies performed and reported results are based on 
only a few cats which may not reflect end stage disease in the larger population of cats infected 
with FIV14,15. 
In FIV infection, there are no distinct biomarker guidelines to stage disease or determine 
increasing risk of illness or progression to end stage disease. The study of FIV infection  presents 
several unique challenges: 1) the lengthy duration of the asymptomatic chronic phase of infection 
makes consistent follow-up difficult and expensive; 2) it is not known what percentage of FIV-
infected cats will succumb to FIV compared to other diseases unrelated to FIV infection; and 3) it 
is not known what factor or factors are definitively associated with progression from 
asymptomatic to symptomatic or end stage disease8,16.Current recommendations for monitoring 
FIV-infected cats in the asymptomatic phase of infection are twice yearly physical examination 
and once yearly routine hematological and serum biochemistry panels to assess for 
abnormalities.17,18 While important for monitoring health, these recommendations only identify 
disease once it has occurred and do not evaluate immune parameters, such as CD4 and CD8 T 
cell counts or viral loads, that may identify FIV disease progression  prior to the occurrence of 
clinical signs of illness or death. 
In this study, it was hypothesized that: 1) FIV-infected cats have an increased incidence of illness 
and mortality rate compared to FIV-uninfected cats; 2) FIV-infected cats have increased markers 
of inflammation and immune activity compared to FIV-uninfected cats and; 3) FIV-infected cats 
residing sanctuary housing will have an increased incidence of illness, mortality and 
inflammation compared to FIV-infected cats living in private homes. The aim of this prospective 
study was to determine the incidence of indicators of illness on physical examination and 
mortality rate in3 cohorts of cats and evaluate the association of lymphocyte immunophenotype, 
inflammatory and hepatic markers of disease to the incidence of indicators of illness and 
mortality rate in these cohorts. Cohorts were comprised of cats naturally infected with FIV 
residing in either sanctuary housing or private homes (<7 cats) and FIV-uninfected control cats 
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residing in private homes. The association between living environment and incidence of 
indicators of illness and mortality rate in FIV-infected cats was also assessed. Percent change in 
lymphocyte immunophenotype, inflammatory and hepatic markers over the 1-year and 6-month 
intervals prior to illness and death was evaluated for associations with progression to illness and 
mortality in FIV-infected cats. The clinical outcome for a subset of 44 FIV-infected cats enrolled 
in this study has been previously reported for the first 22 months of the study period19. 
4.2 Materials and Methods 
4.2.1 Animals 
Cats were enrolled from adoption guarantee shelters (PAWS Chicago and Treehouse Humane 
Society, (Chicago, IL)), the Fitzhugh B. Crews FIV Sanctuary (Memphis, TN) or private homes 
in the Chicago, IL and Memphis, TN metropolitan areas. Cats were considered FIV-infected 
when enzyme linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) were 
both positive at the time of enrollment. Any cat with discordant results had virus isolation (VI) 
performed and this result determined the FIV status. Any cat testing positive for feline leukemia 
virus (FeLV) at enrollment was excluded from the study. Illness was defined by the following : 1) 
a body condition score ≤3 out of 920; or 2) a gingival score (GS) ≥2 out of 321 and any degree of 
gingivostomatits, or tooth root exposure or loose teeth; or 3) nasal or ocular mucopurulent 
discharge; or 4) neoplasia that was visible or palpable on physical examination and confirmed by 
histopathology. At enrollment all cats received a physical examination; only cats that were free of 
evidence of illness as defined above on physical examination were included in this study. 
4.2.2 Laboratory findings 
FIV-infected cats were examined every 6 months and FIV-uninfected cats were examined every 
12 months. At enrollment and at each subsequent examination time point, blood was collected 
and submitted to IDEXX Laboratories (Westbrook, ME) for complete blood count (CBC), plasma 
biochemistry, and FIV/FeLV ELISA test (SNAP® FIV/FeLV test, IDEXX Laboratories, 
Westbrook, ME). Lymphocyte immunophenotyping was performed at IDEXX Laboratories 
(Westbrook, ME) or Purdue University (West Lafayette, IN). Lymphocyte immunophenotyping 
was performed using the protocol described by Lin et al (2013)22. PCR for FIV (FIV Real PCR™ 
Test) was performed at IDEXX Laboratories (West Sacramento, CA) using proprietary primers 
and methodology. VI was performed at the University of Glasgow Centre for Virus Research 
(Glasgow, United Kingdom)23. Necropsies were performed on all cats that died during the study 
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unless the owner declined. Necropsies were performed at the Indiana Animal Disease Diagnostic 
Laboratory at Purdue University by one of the authors (TL). If autolysis interfered with the 
necropsy diagnosis then the cause of death was reported as unknown. Death was considered 
associated with FIV infection if the histopathological diagnosis included bone marrow 
hyperplasia, lymphoid hyperplasia, lymphoid hypoplasia or depletion, or lymphadenomegaly, and 
at least one of the following: lymphoma (at any site), other neoplasia, bacterial tracheitis, 
bronchitis, rhinitis, or conjunctivitis, lymphocytic-plasmacytic or necrotizing enteritis, or 
emaciation 5,24-26. 
The following were evaluated  for  association with progression to illness or death: 1) markers of 
inflammation: hematocrit (HCT), leukocyte count (WBC), neutrophil count (NEUT), lymphocyte 
count (LYMPH), total protein (TP), albumin (ALB), and globulin (GLOB); 2) markers of T cell 
immune status and activation:  CD4 count, CD8 count, CD8βlow, CD4:CD8 ratio and 
CD4:CD8βlow ratio; and 3) markers of hepatic inflammation and injury: alkaline phosphatase 
(AlkP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) activities, 
cholesterol (CHOL) and glucose (GLUC). 
Changes in the laboratory values were assessed at one year prior to onset of illness or death for 
FIV-infected and FIV-uninfected cats that developed illness or died during the study. For the cats 
that did not develop illness or survived to the end of the study, the changes in values were 
assessed at one year prior to the end of the study. Values at 6-months prior to illness, death, or the 
end of the study were also evaluated for FIV-infected cats. 
4.2.3 Statistical analysis 
Data were analyzed using commercially available statistical software (IBM SPSS for Windows 
version 22). Kaplan-Meier method was used to estimate median time to death and onset of illness 
in FIV-uninfected cats, FIV-infected cats living in sanctuary housing, and FIV-infected cats 
living in private households with <7 cats. Cox regression was used to compare hazard rate of 
mortality and illness between the 3 groups of cats with an adjustment for age at enrollment to 
address the concern that older cats are more likely to develop illness or die compared to younger 
cats. Cox regression was also used to assess the association of percent change in lymphocyte 
immunophenotype, inflammatory and hepatic markers with mortality and illness in FIV-infected 
cats over a 6-month and 1-year interval prior to death or illness. The percent change in value for 
analytes was computed using the equation: (T0 – T-1)/T-1 x 100. Where T0 is the sample collected 
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prior to death or at the time of illness and T-1 is the sample collected 1 year or 6 months prior to 
T0. Analytes were investigated using Cox regression with a stepwise procedure as groups 
(immunophenotype panel, inflammatory panel and liver panel) and only the statistically 
significant (P <0.05) markers within each group were reported. Receiving operator curve (ROC) 
analysis was performed for CD4 to determine discriminating ability for illness and mortality. 
4.3 Results 
A total of 174 cats were evaluated and 130 cats (78 FIV-uninfected cats and 52 FIV-infected cats) 
were included in this study and monitored up to 5 years, depending on enrollment and death 
dates. Twenty-six FIV-infected cats lived in sanctuary housing of ≥10 cats and 26 lived in private 
homes of <7 cats. Sixteen FIV-uninfected cats and 3 FIV-infected cats residing in private homes 
were lost to follow-up. Age of the cats at enrollment was not significantly different among the 
three groups (P=0.189, ANOVA test) (Table 1). 
4.3.1 Kaplan-Meier analysis 
The median time to death was 27 months (95% CI 9.5, 44.5) for FIV-infected cats in sanctuary 
housing. FIV-uninfected cats and FIV-infected cats in private homes did not reach the median 
time for death during the 5-year follow-up period (Figure 1). Compared to FIV-uninfected cats, 
FIV-infected cats living in sanctuary housing had an 11.7 (95% CI 4.1, 33.9; P<0.001) fold 
increase in mortality rate and FIV-infected cats living in private homes had a 4.1 (95% CI 1.2, 
14.7; P=0.028) fold increase in mortality rate after adjusting for age at enrollment. FIV-infected 
cats living in sanctuary housing had a 5.1 (95% CI 1.4, 18.2) fold increase in the rate of mortality 
associated with FIV compared to those FIV-infected cats living in private homes. 
The median time to the onset of illness was 23 months (95% CI 14.7, 31.3) for FIV-infected cats 
living in sanctuary housing and 53 months (95% CI 37.3, 68.7) for FIV-infected cats living in 
private homes (Figure 2). Compared to FIV-uninfected cats, FIV-infected cats living in sanctuary 
housing had a 15.1 (95% CI 6.2, 37.0; P <0.001) fold increase in illness rate and FIV-infected 
cats living in private homes had a 3.0 (95% CI 1.1, 8.7; P = 0.037) fold increase in illness rate 
after adjusting for age at enrollment. 
Necropsies were performed on 18 of 21 FIV-infected cats and necropsy findings indicated that 
death was associated with FIV infection in 15 of 26 FIV-infected cats (58%) living in sanctuary 
housing and 3 of 26 FIV-infected cats (12%) living in private homes. Among 25 FIV-infected 
cats that developed illness, 15 died and had necropsy findings associated with FIV infection. 
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There was no difference in mortality rate, following the onset of illness, between FIV-infected 
cats living in sanctuary housing and those living in private homes, after adjusting for age at 
enrollment (P=0.600). The median time to death, following onset of illness, in FIV-infected cats 
with necropsy findings associated with FIV infection was 27 months (95% CI 14.5, 39.5). In cats 
with necropsy findings associated with FIV, those that developed clinical signs of illness had a 
3.8 (95% CI 1.0, 14.1) fold increase in the rate of mortality compared to those cats that did not 
develop illness (P = 0.05). 
4.3.2 Cox regression analysis for mortality rate 
In FIV-infected cats, after adjusting for environment and age at enrollment, a greater decrease in 
TP and ALB in the 1-year interval prior to death was associated with an increased mortality rate 
(P = 0.042 and 0.009, respectively) in the stepwise survival analysis (Table 2). In the 6-month 
interval prior to death, a greater decrease in HCT and ALB was associated with an increased 
mortality rate (Table 2). There were no associations between hepatic markers and mortality in 
FIV-infected cats. 
4.3.3 Cox regression analysis for illness rate 
In FIV-infected cats, after adjusting for environment and age at enrollment, a greater decrease in 
CD4 and ALB (P = 0.002 and 0.039, respectively) and a greater increase in the CD4:CD8 ratio 
were associated with an increased rate of illness in the 1-year time interval prior to the clinical 
signs of illness on physical examination in the stepwise survival analysis (Table 2). Over the 6-
month time interval prior to the onset of clinical signs of illness in FIV-infected cats, a greater 
decrease in CD4 (P = 0.041) and a greater increase in NEUT (P = 0.040) was associated with an 
increased rate of illness (Table 2). There were no associations between hepatic markers and 
incidence of illness in FIV-infected cats. 
There were no associations between inflammatory, immunophenotype, or hepatic markers and 
incidence of illness or mortality in FIV-uninfected cats at the 1 year interval. ROC analysis for 
CD4 did not show adequate ability to discriminate for progression to illness or mortality (data not 
shown). 
4.4 Discussion  
The results of this study show an increase in the rate of mortality and illness in FIV-infected cats 
compared to FIV-uninfected cats; furthermore, FIV-infected cats living in sanctuary housing 
show an increase in rate of mortality and illness compared to FIV-infected cats living in private 
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homes. In FIV-infected cats, a greater increase in TP and a greater decrease in HCT and ALB 
prior to death, was associated with an increased mortality rate in the stepwise survival analysis. A 
greater decrease in CD4and ALB and a greater increase in CD4:CD8 ratio and NEUT prior to the 
onset of illness was associated with an increased rate of illness in FIV-infected cats. These results 
suggest that, in FIV-infected cats, mortality rate is associated with chronic inflammation and 
onset of illness is associated with immune activity. However, given the complicated nature of FIV 
infection, the inflammatory and immune parameters are undoubtedly intertwined. It has been 
reported that alterations in cytokine production, activation of T regulatory (Treg) cells, and 
up-regulation and overexpression of inhibitory T cell surface proteins are associated with 
immunocompromise and chronic inflammation during FIV infection27. Increased 
circulating pro-inflammatory cytokines, such as interleukin-6 (IL-6), IL-1, IL-10, and 
tumor necrosis factor alpha (TNF-α) and decreased circulating IL-12 resulted in an 
immune response that favored humoral (antibody) immunity and decreased cell-mediated 
immunity, leaving the host unable to mount an appropriate immune response to 
pathogens, particularly to intracellular pathogens28-30. Treg cell activation limits the 
amount of IL-2 produced; a key cytokine produced by T cells to propagate an adaptive 
immune response to pathogens31,32. Up-regulation and overexpression of surface proteins, 
CTLA-4 and B7.1, on activated T cells act as co-stimulatory signals between T cells and 
induce a state of anergy (immune inactivity) 33-35. The combination of these factors may 
create a paradoxical situation, in which, immune activation responds to inflammatory 
signals but stimulates dampening of the adaptive immune response, rather than 
proliferation of a protective response. 
The definition for clinical signs of illness were chosen based on previous studies that reported 
FIV-infected cats have a higher risk of upper respiratory infections, dental disease, loss of body 
condition and neoplasia compared to FIV-uninfected cats10,13,36,37. The results of this study further 
support that FIV-infected cats have an increased rate of illness characterized by loss of body 
condition and respiratory and oral disease and neoplasia. Some clinical signs included in criteria 
for clinical signs of illness, such as dental disease and neoplasia, may not be readily apparent to a 
lay person. Therefore, it remains important for owners to follow current retroviral guidelines for 
FIV-infected cats to be examined twice yearly regardless of health status of a cat17,18. 
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An increased rate of mortality and illness observed in the FIV-infected cats living in sanctuary 
housing compared to FIV-infected cats in private homes is not entirely unexpected. Identifying an 
underlying cause of illness in enrolled cats was beyond the scope of this study however, recent 
publications in shelter medicine have reported increased illness, particularly upper respiratory 
infection (URI), among cats living in shelter environments 38-41. Although certain upper 
respiratory tract pathogens are almost ubiquitous in the cat population, several studies have 
reported an increased prevalence of feline herpesvirus-1 (FHV-1), feline calicivirus (FCV), 
Bordetella bronchiseptica, Chlamydophila felis and Mycoplasma species within shelter settings38-
41. Several guidelines have made recommendations for care and management of large multi-cat 
housing situations and efficient use of resources including medical management, quarantine and 
isolation to limit pathogen exposure, reduction of fomite exposure via personnel, and adequate 
housing facilities (including space and ventilation) to reduce incidence of infectious diseases42,43. 
In addition to basic housing construction requirements, alleviation of environmental and inter-cat 
stress is also important and has been associated with increases in stress hormones. Recent studies 
have shown increases in the urine cortisol-to-creatinine (UCC) ratio in cats housed under 
differing housing conditions within shelter situations.  UCC were increased in cats not exhibiting 
outward signs of stress44. UCC levels were also reported to be higher in privately owned cats 
visiting a veterinarian’s office compared to UCC levels in the same cats when at home, 
suggesting that cats are quite sensitive to environmental stressors45. 
The results of this study show an increased rate of mortality in FIV-infected cats, both residing in 
sanctuary housing (age-adjusted rate ratio 11.7) and in private homes (age-adjusted rate ratio 4.1) 
compared to FIV-uninfected cats. Recent studies have reported that FIV-infected cats may 
succumb to illnesses unrelated to FIV infection and that the lifespan of an FIV-infected cat is not 
statistically different from an FIV-uninfected cat1,4,46. While a few FIV-infected cats in this study 
died of causes unrelated to FIV infection, such as trauma and urethral obstruction, the majority 
(86%) of FIV-infected cats in this study had necropsy findings consistent with FIV infection 
without other differential diagnostic findings for cause of death. Importantly, in this study, FIV-
infected cats that developed clinical signs of illness had an increased mortality rate after 
adjustment for age and environment. These results support an association between clinical signs 
of illness on physical examination and progression to early mortality, however, as previously 
reported in the literature the time to death following onset of clinical signs is variable between 
FIV-infected cats. In studies of naturally acquired infection, the time to death, following 
observation of clinical signs of illness, has ranged from 1 month to more than 41 months47. 
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The choice of CBC and chemistry parameters evaluated in this study was made based on 
evidence that FIV causes chronic inflammation, immunosuppression, chronic disease and 
depletion of lymphoid cells, particularly in the mucosal lymphoid tissue28,29,48-53. 
The association of a greater decline in HCT and ALB with mortality may be explained by chronic 
inflammation associated with FIV infection, although inflammation associated with concurrent 
infections or neoplasia may also play a role. Increased circulating pro-inflammatory cytokines, 
interleukin-1β (IL-1β), IL-6 and tumor necrosis-alpha (TNF-α), cause production of positive 
acute phase proteins in the liver; at the same time the inflammatory cytokines interfere with 
production of negative acute phase proteins such as ALB54,55. This loss of ALB during chronic 
FIV infection may be associated with higher levels of circulating pro-inflammatory cytokines that 
have been reported in cats in the symptomatic stage of FIV infection compared to those in the 
asymptomatic stage of infection50. It may also be that ALB was lost via the kidneys or 
gastrointestinal tract (GIT) but direct conclusions cannot be drawn from this study. Renal values 
were not assessed for their association with illness or mortality in this study and urine protein-to-
creatinine ratio was not performed in these cats. TP, GLOB, CHOL and GLU were not associated 
with illness or mortality suggesting that gastrointestinal loss of ALB was not an issue but 
intestinal biopsies and intestinal fatty acid binding protein levels were not performed to assess 
GIT integrity. In terms of application, a further 10% decrease in ALB in FIV-infected cats would 
correlate with a 3.3 fold increase in mortality rate over a 1-year interval and 2.2 fold increase over 
a 6-month interval (𝑒𝑒(−10∗−0.119) and 𝑒𝑒(−10∗−0.079), respectively). The association of a greater 
decrease in HCT with mortality rate might be explained by anemia of chronic disease. This 
process has been reported to be associated with chronic inflammatory conditions and neoplastic 
disease, such as lymphoma, and may result in reduced erythroid production or iron deficiency 
associated shortening of the red blood cell life span. 
In FIV-infected cats, a greater decrease in the percent change of CD4 was associated with an 
increased illness rate over the 1-year and 6-month time intervals. CD4 T cells are a driving force 
of the adaptive immune system and play a key role in orchestrating the humoral and cell-
mediated responses to infection. The progressive loss of CD4 T cells in FIV-infected cats during 
the acute and asymptomatic stages of infection compared to FIV-uninfected cats has been widely 
reported; CD4 T cell counts in the end stage of FIV infection are not often reported. While CD4 T 
cell counts of <21 cells/mL in FIV-infected cats with end stage disease have been reported; it has 
also been reported that FIV-infected cats have tolerated low (<50 cells/mL) CD4 T cell levels 
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without showing outward signs of clinical illness during the asymptomatic stage of infection. 
Although the results of this study show an association between CD4 T cell percentage and illness 
rate, the low hazard rate ratio suggests that a greater change in CD4 T cells would not be 
sufficient as a single tool to indicate progression to disease. A greater decrease of percent change 
in CD4 T cells in cats in this study had limited practical application. For example, a further 50%  
decrease in CD4 T cells  would only result in a 1.9 fold increase in illness over a 1–year interval 
and 1.7 fold increase in illness over a 6-month interval (𝑒𝑒(−50∗−0.013) and 𝑒𝑒(−50∗−0.011) , 
respectively). 
A greater increase in the CD4:CD8 ratio over a 1-year interval and NEUT over a 6-month interval 
was associated with an increased illness rate. Goto et al14 reported an increase in the CD4:CD8 
ratio for cats in the end stage  of disease compared to those in the chronic stage of disease. This 
change in ratio was attributed to loss of both CD4 and CD8 cells in the end stage of disease 
because the end stage ratio was still markedly lower than that of the asymptomatic cats. It is 
difficult to determine why a greater increase in the CD4:CD8 ratio was associated with illness in 
these study cats. It is possible that the timing of illness was early enough in the disease course 
that a sufficient number of CD4 T cells were still present in relation to CD8 T cells and kept the 
CD4:CD8 ratio at a higher level. Conversely, it may be that expansion of CDβlow cells within the 
CD8 T cell population was not at a point great enough to decrease the CD4:CD8 ratio in 
comparison to the CD4 T cell population. Due to the fact that these infections were naturally 
acquired without a known infection date, it is impossible to know the duration of infection and 
how this may have impacted immunosuppression and T cell levels. The association of a greater 
increase in NEUT with illness may reflect a normal fluctuation of cell counts in this small group 
of FIV-infected cats but it is also possible that the immune response mounted by the FIV-infected 
cats was still adequate at this stage in chronic disease. 
There are several limitations to this study that may have affected our results. Survival analysis 
was used to statistically account for loss to follow-up in the different groups of cats. However, an 
assumption that the reasons cats were lost to follow-up were unrelated to mortality and illness 
cannot be validated. Our use of a stepwise procedure to identify significant associations between 
markers and outcomes of interest is considered exploratory and a confirmatory study is needed. 
The cats enrolled in this study were all naturally infected with FIV and the exact date of infection, 
the infecting dose at the time of infection and duration of infection are unknown. Given these 
unknowns direct longitudinal comparisons among the cats was not possible. Additionally, as 
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these cats were all sourced from shelters, the age assigned at the time of shelter admission, and 
that used for the age at enrollment, was an estimate. Given the long term chronic nature of FIV 
infection the time frame of the study (up to five years) might not have been long enough to realize 
the natural disease progress of FIV-infected cats. 
4.5 Conclusion 
Cats infected with FIV had a higher incidence rate of mortality and illness compared to FIV-
uninfected cats and those that residing in sanctuary housing had a higher incidence rate of 
mortality and illness compared to FIV-infected cats in private homes with <10 cats. Percent 
change in inflammatory markers ALB and NEUT and lymphocyte immunophenotype were 
associated with an increased rate to illness or death in FIV-infected cats, however, the 
incremental changes and associations are considered exploratory in this small group of cats and 
cannot be extrapolated to FIV-infected cats in general. Furthermore, the change in rate ratio for 
lymphocyte immunophenotype values was small and may not be practically important as a single 
monitoring tool for illness and mortality. These results do support the hypothesis that 
inflammation and immune activity are important components associated with FIV disease 
progression. The results also highlight the importance of housing environment on illness and 
mortality in FIV-infected cats, which is key in defining best management practices as the animal 
sheltering community more commonly seeks to place FIV-infected cats for adoption. Further 
investigation into the interaction between inflammatory pathways, immunophenotype changes 






Figure 4.1. Survival curves for Mortality in FIV-infected and FIV-uninfected cats 






Figure 4.2. Survival curves for Illness in FIV-infected and FIV-uninfected cats 




Table 4.1. Age and Sex of FIV-infected and FIV-uninfected cats 
a All cats were previously spayed or neutered at time of enrollment 
b Median age at enrollment for FIV-infected and FIV-uninfected cats 
 Groups 
 FIV-negative  
n = 78 
FIV-positive 




 n = 26 
Males (%)a 50 (64) 19 (73) 18 (69) 
Females (%)a 28 (35) 7 (27) 8 (31) 














Table 4.2. Analytes that are significantly associated with mortality and illness in FIV-
infected cats investigated in Cox regression with a stepwise procedure 
a  A negative coefficient indicates that a greater decrease in the marker prior to death/illness is 
associated with an increase in the rate of mortality and illness. A positive coefficient indicates 
that a greater increase in the marker prior to death/illness is associated with an increase in the rate 
of mortality and illness. 
Mortality Variable Coefficienta P-value 
1 year interval in FIV+ cats TP 0.072 0.042 
 ALB -0.119 <0.001 
6 month interval in FIV+ cats HCT -0.049 0.001 
 ALB -0.079 0.004 
Illness Variable Coefficienta P-value 
1 year interval in FIV+ cats CD4 -0.02 0.002 
 CD4:CD8 ratio 0.009 0.015 
 ALB -0.043 0.039 
6 month interval in FIV+ cats CD4 -0.011 0.041 
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Research into FIV infection is complicated due to the lengthy chronic asymptomatic phase of 
disease, inability to identify cats that will progress to end stage disease, lack of factors associated 
with disease progression and expense associated with long term monitoring. To date, the majority 
of longitudinal research has focused on the acute and early chronic stages of infection in 
experimental models of FIV infection1-4. Research investigating the transition from late chronic to 
end stage infection is sparse; published findings are based primarily on the outcome information 
of only a few cats with natural infection which makes extrapolation to the general FIV-infected 
population difficult5-7. 
This research project followed a cohort of cats naturally infected with FIV and uninfected control 
cats over a period of up to 5 years. Comparisons were made between FIV-infected cats and FIV-
uninfected cats and between FIV-infected cats in sanctuary housing and FIV-infected cats in 
private homes of <7 cats. The purpose of this study was to determine temporal patterns in routine 
laboratory parameters and lymphocyte immunophenotype, describe the illness and mortality rates, 
and assess the association of inflammatory, lymphocyte immunophenotype and hepatic markers 
with incidence of illness and mortality.  
The most striking finding of this study was the disparity in hazard rates for illness and mortality 
among the groups of cats. Compared to FIV-uninfected cats, mortality rate was increased 11.7 
fold in FIV-infected cats in sanctuary housing and 4.1 fold in FIV-infected cats in private homes. 
The mortality rate was increased 5.1 fold for FIV-infected cats in sanctuary housing compared to 
FIV-infected cats in private homes. Compared to FIV-uninfected cats, the illness rate was 
increased 15.1fold for FIV-infected cats in sanctuary housing and 3.0 fold for FIV-infected cats in 
private homes. Furthermore, FIV-infected cats that became ill had a 3.8 fold increase in mortality 
rate compared to FIV-infected cats that did not become ill. These findings support an association 
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between clinical signs of illness and early mortality, however, time to death following the onset 
of clinical signs was variable and similar to the 1 month to greater than 41 months that has been 
previously published5. Direct comparison of illness and mortality rates between FIV-infected cats 
living in different environments has not been previously reported. These results were surprising, 
although not completely unexpected. Determination of causes for increased illness and mortality 
rates was beyond the scope of this study, however, it has been reported that cats living in shelter 
housing have a high prevalence of illness; particularly upper respiratory infections8-11. Increased 
incidence and prevalence of upper respiratory infections in shelters have been associated with 
increased numbers of cats within the shelter, ineffective cleaning and disinfecting protocols, lack 
of standard vaccination protocols, presence of upper respiratory disease within the shelter, and 
lack of quarantine and isolation procedures for cats entering a facility8-11. Several studies have 
reported higher urine cortisol-to-creatinine (UCC) levels in cats under certain shelter housing 
conditions, and in cats at a veterinary facility compared to UCC levels in the same cats at home 
which suggests that cats are sensitive to environmental conditions8,12,13. 
Differences in temporal patterns for CD4 and total CD8 T cells and lymphocyte counts showed a 
greater loss in FIV-infected cats compared to uninfected cats. CD4 T cells are the primary target 
of FIV infection but CD8 T cells can also be infected and progressive loss of T cells through cell 
mediated, apoptotic or anergic mechanisms have been reported14-16. Although anticipated, 
differences in temporal patterns for CD8βlow cell counts were not seen, despite CD8βlow cell 
counts being consistently higher in FIV-infected cats. It is possible that maximal expansion of 
CD8βlow cells had already occurred in the FIV-infected cats. This may have impacted the 
CD4:CD8 ratios, as they were lower in FIV-infected cats, as expected, but no difference in 
temporal pattern was seen. 
Notable differences in temporal patterns between FIV-infected cats in sanctuary housing and cats 
in private homes were seen for absolute white blood cell counts and total protein values. White 
blood cell counts and total protein levels increased in FIV-infected cats in sanctuary housing 
compared to decreased values in FIV-infected cats in private homes. Median total protein levels 
for both FIV-infected groups were above the reference interval throughout the study. The 
increased total protein levels may reflect hypergammaglobulinemia thought to be secondary to B 
cell stimulation in FIV-infected cats. The sanctuary housed FIV-infected cats had consistently 
higher median globulin values and absolute neutrophil counts, and lower median albumin values 
compared to cats in private homes, although differences in temporal patterns were not seen. These 
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findings may reflect the increased illness rate in sanctuary housed cats and suggest an increased 
inflammatory process that may be related to increased illness or stress within the environment. 
Associations between inflammatory and lymphocyte immunophenotype markers and increased 
illness and mortality rates were found in FIV-infected cats. This lends further support to 
previously published findings linking chronic inflammation and alterations in T cells with chronic 
FIV infection2,3,17-19. A greater decrease in CD4 T cell and albumin percentages and greater 
increase in CD4:CD8 ratio and neutrophil percentages were associated with increased illness rate. 
Increase in mortality rate was associated with a greater increase in total protein and greater 
decrease in albumin and hematocrit percentages. However, the individual hazard rate associated 
with each marker was weak. Inflammation in chronic disease states has been associated with 
albumin loss. This is thought to be secondary to increased pro-inflammatory cytokine and 
positive acute phase protein production and decreased negative acute phase protein production, 
such as albumin20,21. FIV-infected cats are reported to have increased circulating pro-
inflammatory cytokines and this may be a potential cause of the association between decreased 
albumin and increased illness and mortality19. Loss of CD4 T cells following FIV infection is 
well documented and association between decreased CD4 T cells with illness and mortality was 
expected, however, the associations were anticipated to be much stronger. This supports previous 
postulations that cats can tolerate low CD4 T cell levels without developing disease. Previously 
published studies have reported conflicting observations between clinical signs of illness and low 
CD4 T cell counts in FIV-infected cats7,22.  
Overall, this study showed an increased risk of illness and death in FIV-infected cats compared to 
uninfected cats. Furthermore, it uncovered a discrepancy in illness and mortality rates, not 
previously reported in the literature, between FIV-infected cats living in sanctuary housing and 
those living in private homes. This raises the question of whether environment plays a role in 
illness and mortality associated with FIV infection. Further investigation into the role of 
environment in FIV disease progression is warranted; particularly as animal shelters increasingly 
seek to adopt rather than euthanize FIV-infected cats. The associations between inflammatory and 
lymphocyte immunophenotype markers and illness and mortality rates were considered 
exploratory and extrapolation to the general population of FIV-infected cats cannot be made; 
especially as associations were weak. However, given the lack of readily available monitoring 
techniques to assess disease progression in FIV-infected cats, further investigation into these 
health parameters may be necessary. Ultimately, new, reliable and easily performed diagnostics 
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are needed to better assess the immune response and inflammation associated with long term, 
chronic FIV infection. Better tools to assess immune health in relation to the progression of FIV 
infection will lead to better management techniques and earlier medical intervention to preserve 
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